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ABSTRACT 
  A series of novel quinoline-chalcone derivatives were designed, synthesized and 
evaluated for their antiproliferative activity. Among them, compound 24d exhibited 
the most potent activity with IC50 values ranging from 0.009 to 0.016 μM in a panel of 
cancer cell lines. Compound 24d also displayed a good safety profile with LD50 value 
of 665.62 mg/kg by intravenous injection, and its hydrochloride salt 24d-HCl 
significantly inhibited tumor growth in H22 xenograft models without observable 
toxic effects, which was more potent than that of CA-4. Mechanism studies 
demonstrated that 24d bound to the colchicine site of tubulin, arrested cell cycle at the 
G2/M phase, induced apoptosis, depolarized mitochondria and induced reactive 
oxidative stress (ROS) generation in K562 cells. Moreover, 24d has potent in vitro 
anti-metastasis, in vitro and in vivo anti-vascular activities. Collectively, our findings 
suggest that 24d deserves to be further investigated as a potent and safe anti-tumor 
agent for cancer therapy. 
 
INTRODUCTION 
Microtubules provides a dynamic scaffold for maintenance of cell structure, protein 
trafficking, chromosomal segregation, and mitosis.1 They are long, hollow structures 
that are mainly composed of α- and β-tubulin dimers. 2-4 Microtubule-targeting agents 
(MTAs) including microtubule stabilizers or destabilizers can interfere with 
microtubule dynamics, leading to mitotic blockade and cell apoptosis.5 In recent 
decades, MTAs that bind to the colchicine site have been attracting the interest of 
medicinal chemists because of their advantages over other site binders; these MTAs 
have simpler structures, improved aqueous solubility, broad therapeutic index, and 
reduced multidrug resistance (MDR) effects as comparing with other site binders.6-12 
Notably, colchicine binding site inhibitors (CBSIs) can induce morphological changes 
in endothelial cells, thus provoking a rapid disrupt of existing tumor vasculature,  
and thus are commonly designated as vascular disrupting agents (VDAs).13, 14  
Chalcones that bear an α, β-unsaturated ketone moiety represents a key structural 
motif in the plethora of biologically active molecules including synthetic and natural 
products. They have shown a broad range of biological activities such as antioxidant, 
antibacterial, antifungal, anti-HIV, anti-leishmanial, antimalarial, anti-inflammatory, 
and anticancer properties.15 In the development process of CBSIs, the α, β-unsaturated 
ketone moiety of chalcones was recognized as a privileged structure.16-20 
Representative anti-tubulin chalcones, presented as compounds 1 and 2 (Figure 1a), 
showed remarkable antiproliferative activities.21 The more preferential s-trans 
conformation adopted by 2, which could interact with tubulin more easily, led to more 
potent cytotoxicity than 1. Another chalcone compound reported by Li’s group was 
compound 3, which exhibited excellent antipoliferative activity with IC50 values 
ranging from 3 to 9 nM against a panel of cancer cell lines.22 Our previous work on 
the modification of compound 1 also led to a novel chalcone analog 4, which 
displayed both potent anti-vascular and anti-tumor activities.23   
Nitrogenous molecules, such as pyridines and quinolines, have numerous 
advantages over other non-nitrogenous molecules. The introduction of nitrogen atom 
greatly improves the basicity of molecules due to its basic characteristic, and nitrogen 
atom may form a strong hydrogen bond with the targets. Another important property 
is the polarity which can be used as a mean of reducing the lipophilic character, 
improving water solubility and oral absorption.24 The quinoline motif is frequently 
found in natural alkaloids that exhibit a wide range of biological activities. The 
quinoline ring system-containing drugs, such as quinine, chloroquine, mefloquine and 
amodiaquine, are used as efficient treatments of malaria.25 Quinoline analogs also 
exhibit anticancer activities with different mechanisms, including alkylating agents, 
tyrosine kinase inhibitors and tubulin inhibitors.26  
Considering the poor aqueous solubility that impeded the clinical development of 
some CBSIs,27 incorporation of nitrogenous heterocycles, which could be salified 
with acids, may improve water solubility. Some examples of tubulin inhibitors 
bearing a quinoline skeleton are listed in Figure 1b, such as compounds 528, 629 and 7 
- 1130-34. Recently, the work performed by Alami et al. also proved that a quinoline 
ring as shown in compound 12 can replace the 3,4,5-trimethoxyphenyl moiety and 
provide compounds with more potent activities.35 Their docking studies predicted that 
the N-1 atom of quinoline formed a hydrogen bond with the critical residue Cys 241, 
which was further supported by the later disclosed crystal structure of tubulin in 
complex with 11.34 Thus, the quinoline moiety might be a surrogate of the 
3,4,5-trimethoxyphenyl moiety when binding to the colchicine site.  
Our group has concentrated on discovering and developing novel anticancer agents 
targeting the tubulin-microtubule system.23, 36, 37 In our continuing works on the 
structural modification of the parent compound 1 around the 3,4,5-trimethoxyphenyl, 
which led to the discovery of a series of novel quinoline-chalcone derivatives (Figure 
2). Meanwhile, given previous studies showed that the indole moiety was an 
alternative structure of the isovanillic ring.38, 39 Thus, new quinoline-chalcones that 
contain an indole moiety were also designed and synthesized. Herein, we would like 
to report their synthesis and anti-tumor activities in vitro and in vivo. In addition, the 
underlying cytotoxic mechanisms of the representative compound 24d are also 
elucidated. 
Figure 1. a) Representative anti-tubulin chalcones or chalcone analogs; b) Tubulin inhibitors 
bearing quinoline and quinazoline skeletons. 
 
 
Figure 2. Design strategy of novel quinoline-chalcone derivatives. 
 
RESULTS AND DISCUSSION 
  Chemical Synthesis. In Alami’s previous work,35 the effects of different 
substitutions at the C-2 position of quinoline were investigated in detail with a methyl 
group being the most active. Thus, 2-methylquinoline was first chosen to replace the 
3,4,5-trimethoxyphenyl moiety of compound 1. The synthetic route of key 
intermediates acetylquinoline 16 and propionylquinoline 21 was outlined in Scheme 1. 
2-Methylquinoline-4-carboxylic acid (14) was prepared by refluxing the 
commercially available material isatin (13) with acetone under basic conditions, 
which was further converted into Weinreb amide 15, and 15 reacted with 
methylmagnesium bromide (CH3MgBr) to obtain acetylquinoline 16 in high yields. 
Disappointingly, this method was not applicable for the synthesis of 
propionylquinoline 21 due to the overreaction of 21 with ethylmagnesium bromide 
(C2H5MgBr) resulting in a great decreased yield. Thus, we attempted a tedious but 
effective route to synthesize 21. 2-Methylquinoline-4-carbaldehyde (19) was prepared 
by the oxidation of 18 according to the previous report [40]. Then, 19 underwent 
nucleophilic attack by CH3CH2MgBr to obtain 20, which was subsequently oxidized 
to produce the propionylquinoline 21. 
  The designed target compounds 24a-o containing a 2-methylquinoline moiety were 
synthesized using acetylquinoline 16 or propionylquinoline 21 with various 
commercially available aldehydes via aldol condensation reactions (Scheme 2). 
Compound 24a and 24b bearing amino groups were synthesized using 
3-nitro-4-methoxybenzaldehyde (22) in the condensation steps, after which the nitro 
group was reduced to amino group to afford 24a and 24b. Similarly, the MEM 
protective group was used to synthesize 24c and 24d bearing an isovanillic ring. The 
aldol reactions of 16 or 21 with various benzaldehydes or indole formaldehydes 
provided the target compounds 24e-o.  
 
Scheme 1. The synthetic route of key intermediates 16 and 21a. 
 
aReagents and conditions: (a) 85% KOH aqueous, acetone, 50 ℃, 24 h, 82.3%; (b) 
CH3NHOCH3-HCl, EDCI, HOBt, DMAP(cat.), DCM, rt, 2 h, 83.1%; (c) CH3MgBr, THF, 0 ℃ to 
rt, 2 h, 84.0%; (d) i) oxalyl chloride, DMF (cat.), DCM; ii) C2H5OH; 72.2% over two steps; (e) 
NaBH4, CH3OH; 0 ℃ to rt, 4 h, 63.5%; (f) Dess-Martin reagent, DCM; 2 h, rt, 65.1-80.0%; (g) 
C2H5MgBr, THF, 0 ℃ to rt, 2 h, 74.1%. 
  Subsequently, compounds bearing a quinoline moiety with varying substitutions at 
the C-2 position were designed and synthesized. Compounds 29a and 29b with 
hydroxymethyl and formyl groups at the C-2 position of the quinoline ring were 
synthesized as shown in Scheme 3. Intermediate 28 was prepared by a rearrangement 
reaction of quinoline-N-oxide 27, and a further aldol reaction with MEM protected 
isovanillin 25 led to 29a, which was oxidized to formyl substituted target compound 
29b. 
Scheme 2. The synthetic route of key intermediates 24a-oa. 
   
aReagents and conditions: (a) NaOH, EtOH, rt, 30 min, moderate yields; (b) Fe, AcOH, EtOH, 
reflux; 62.5-73.2%; (c) 10% HCl, EtOH, 30 min, 85-95%; (d) different benzaldehydes, NaOH, 
EtOH, rt, 30 min, moderate yields or different indole formaldehydes, piperidine, EtOH, reflux, 
moderate yields. 
Scheme 3. The synthetic route of key intermediates 29a and 29ba.  
 
aReagents and conditions: (a) m-CPBA, DCM, 2 h, rt, 89.0%; (b) i) Ac2O, reflux, 2 h, 86.2%; ii) 
10% NaOH aqueous, CH3OH, 30 min, 88.2%; (c) i) NaOH, EtOH, rt, 30 min; ii) 10% HCl, EtOH, 
reflux, 30 min; 43.7%; (d) IBX, DMSO, rt, 30 min, 74.9%. 
Chloro-substituted propionylquinoline 36 was prepared as shown in Scheme 4. 
Intermediate 30 was prepared by refluxing isatin 13 with malonic acid in glacial 
acetic acid, following a chlorination by POCl3 leading to 2-chloroquinoline-4- 
carboxylic acid (31), which was converted to propionylquinoline 36 according to the 
synthesis method of intermediate 21. Propionylquinolines 37a-c were prepared by 
nucleophilic reactions of 36 with secondary amines. Because primary amines can 
react with the ketone group of 36 to form Schiff bases, we used 35, the precursor of 
36, to react with various primary amines followed by oxidations by IBX to afford 
intermediates 39a-d. Cyano containing propionylquinoline 40 was prepared by a 
Pd-catalyzed coupling reaction of 36 with Zn(CN)2, and a methoxy group was 
introduced by a nucleophilic reaction of 36 with NaOCH3 to give intermediate 41. In 
our attempts to introduce a mesyl group to the C-2 position of quinoline, the lactam 
42 was occasionally obtained, which was then used for the next derivation to 
synthesize compound 29m. Propionylquinoline 45 was prepared using commercially 
available quinolone-4-carbaldehyde (43) as the starting material. 
 
Scheme 4. The synthetic route of key intermediates a.  
 aReagents and conditions: (a) malonic acid, AcOH, reflux, overnight, 85.6%; (b) POCl3, reflux, 2 
h, 72.3%; (c) i) oxalyl chloride, DMF (cat.), DCM, 0 ℃ - rt, 1 h; ii) C2H5OH, rt, 30 min, 72.0% 
over two steps; (d) NaBH4, CH3OH, 0 ℃ - rt, 2 h, 83.8%; (e) Dess-Martin reagent, DCM, 30 min, 
rt, moderate to high yields; (f) C2H5MgBr, THF, 0 ℃ - rt, 2 h, 72.9%; (g) various secondary 
amines, EtOH, 80 ℃, sealed tube, 81-88%; (h) various primary amines, EtOH, 150 ℃, sealed tube, 
2 d, moderate yields; (i) IBX, DMSO, 30 min, rt, 45.0-56.9%; (j) Pd(PPh3)4, Zn(CN)2, DMF, 
120℃, 2 h, 87.0%; (k) NaOCH3, CH3OH, reflux, 4 h, 88.4%; (l) CH3SO2Na, H2O, AcOH, 90 ℃, 
overnight, 87.3%. 
 
The synthetic route of target compounds 29c-n was outlined in Scheme 5. 
Intermediates 36, 37a-c, 39a-d, 41, 42 and 45 underwent aldol reactions with MEM 
protected isovanillin 25, after which MEMs were removed to obtain target compounds 
29c-m. The cyano group hydrolyzed to ethyl ester led to compound 29n in the aldo 
condensation reaction of intermediate 40 with 25.  
Scheme 5. The synthetic route of target compounds 29c-na.  
 
aReagents and conditions: (a) i) NaOH, EtOH, rt, 30 min, moderate yields; ii) 10% HCl, EtOH, 
reflux, 30 min, 85-95%. 
 
BIOLOGY 
Antiproliferative Activities and the structure activity relationships (SARs). 
The in vitro antiproliferative efficacy of target compounds 24a-q with a 
2-methylquinoline moiety were first assessed by MTT assays using human chronic 
myelogenous leukemia cell K562 and compared to the reference compound CA-4. As 
shown in Table 1, except for compounds 24j-k and 24n-o, which had indole moieties 
as ring B, all of the newly synthesized compounds exhibited decent antiproliferative 
activities in a nanomolar range. Among which, compounds 24b and 24d, featuring 
3-amino-4-methoxyphenyl or 3-hydroxy-4-methoxyphenyl moieties, displayed the 
most potent activity with IC50 values of 0.011 and 0.009 μM, respectively, which were 
comparable to that of CA-4 (IC50 = 0.011 μM) and were approximately 6-fold more 
potent than the parent compound 1 (IC50 = 0.060 μM). The methyl substituent at the 
α-position of the unsaturated carbonyl group improved the activity (24a vs. 24b, 24c 
vs. 24d and 24k vs. 24l), which was similar to the results in previous reports [21,22]. 
Additionally, different substituted indole derivatives 24i-q were synthesized and 
evaluated for their antiproliferative activity. However, most of this series displayed 
lower activities (IC50 > 1 μM) than the phenyl counterparts, except compounds 24l and 
24m, of which the unsaturated double bonds were substituted at the C-5 position on 
indole moiety. Besides, the methyl substituent at the N-1 position of the indole (24m) 
increased the activity for approximately 5-fold when compared to the non-substituted 
counterpart 24l.  
  The effects of substitutions at the C-2 position on the quinoline moiety on activity 
were further investigated with both the isovanillic ring and methyl substituted α, 
β-unsaturated ketone retained. Thus, compounds 29a-n with different substituted 
quinolines were synthesized and evaluated for their antiproliferative efficacy. As 
shown in Table 1, all compounds 29a-n displayed decent activities except 29m, which 
had a lactam rather than the quinoline ring. Steric hindrance of the groups at the C-2 
position on the quinoline moiety seemed to exert a critical influence on the activity, as 
compounds with smaller substitutions such as CH3 (24d, IC50 = 0.009 μM), NHCH3 
(29g, IC50 = 0.018 μM), OCH3 (29k, IC50 = 0.030 μM), and H (29l, IC50 = 0.015 μM) 
were more active than other compounds with larger groups. Interestingly, the CH3 
substituted compound 24d exhibited a slightly more potent activity than the 
correspond non-substituted counterpart 29l, though the methyl group has a larger 
steric hindrance than hydrogen.  
  The positive results of the antiproliferative activities of newly designed 
quinoline-chalcone derivatives against K562 cells led us to further evaluate the 
biological functions against more cancer cell lines. Four additional cancer cell lines, 
including human hepatocellular carcinoma (HepG2), epidermoid carcinoma of the 
nasopharynx (KB), human colon cancer cells (HCT-8) and human breast cancer cells 
(MDA-MB-231), were chosen for further evaluation. The cytotoxic data of 
representative compounds against these four cancer cell lines were shown in Table 2, 
which indicated that the IC50 values of selected compounds against these four cancer 
cell lines were in nanomolar ranges. The K562 cell was the most sensitive cell line 
among the five cancer cell lines tested, and the most active compound 24d exhibited 
comparable activity to the reference compound CA-4 with IC50 values ranging from 
0.009 to 0.016 μM. Notably, 24d displayed an approximately 6-fold improvement in 
activity compared with the parent compound 1. The SARs of the newly synthesized 
compounds were summarized in Figure 3. 
Table 1. Antiproliferative activities of compounds 24a-q and 29a-n against K562 cell linea. 
Compd. IC50 values (μM)b Compd. IC50 values (μM)b 
K562 K562 
24a 0.850 ± 0.032 29b 0.110 ± 0.008 
24b 0.011 ± 0.001 29c 0.053 ± 0.006 
24c 0.127 ± 0.07 29d 0.049 ± 0.001 
24d 0.009 ± 0.001 29e 0.315 ± 0.033 
24e 0.108 ± 0.009 29f 0.153 ± 0.014 
24f 1.055 ± 0.040 29g 0.018 ± 0.003 
24g 0.069 ± 0.007 29h 0.040 ± 0.005 
24h 0.563 ± 0.021 29i 0.058 ± 0.008 
24i > 1 29j 0.330 ± 0.028 
24j > 1 29k 0.026 ± 0.004 
24k > 1 29l 0.015 ± 0.001 
24l 0.346 ± 0.015 29m 1.239 ± 0.055 
24m 0.074 ± 0.009 29n 0.120 ± 0.015 
24n > 1 1 0.060 ± 0.007 
24o > 1 CA-4 0.011 ± 0.001 
29a 0.050 ± 0.004   
a Cells were treated with different concentrations of the compounds for 72 h. Cell viability was 
measured by an MTT assay as described in the Experimental Section. 
b IC50 values are indicated as the mean ± SD (standard deviation) of at least three independent 
experiments. 
Table 2. Antiproliferative activities of representative compounds against four cancer cell linesa. 
Compd. 
IC50 values (μM)b 
HepG2 KB HCT-8 MDA-MB-231 
24a 0.223 ± 0.021 0.189 ± 0.015 0.21 ± 0.010 0.195 ± 0.011 
24b 0.036 ± 0.008 0.025 ± 0.003 0.036 ± 0.005 0.063 ± 0.009 
24c 0.121± 0.010 0.123 ± 0.022 0.137 ± 0.015 0.112 ± 0.013 
24d 0.015± 0.002 0.016 ± 0.001 0.015 ± 0.003 0.015 ± 0.004 
24l 0.226± 0.021 0.429 ± 0.034 0.421 ± 0.035 0.425 ± 0.025 
24m 0.111± 0.009 0.124 ± 0.013 0.135 ± 0.011 0.220 ± 0.016 
29a 0.165± 0.012 0.231 ± 0.022 0.242 ± 0.018 0.209 ± 0.015 
29c 0.187± 0.014 0.237 ± 0.023 0.227 ± 0.026 0.183 ± 0.014 
29d 0.057± 0.003 0.043 ± 0.008 0.052 ± 0.006 0.048 ± 0.005 
29g 0.027± 0.003 0.029± 0.006 0.040 ± 0.009 0.043 ± 0.007 
29k 0.038± 0.002 0.052 ± 0.006 0.061 ± 0.008 0.052 ± 0.008 
29l 0.024± 0.001 0.026 ± 0.001 0.037 ± 0.003 0.030 ± 0.007 
1 0.102± 0.010 0.108 ± 0.005 0.104 ± 0.010 0.102 ± 0.009 
CA-4 0.012± 0.001 0.012 ± 0.002 0.015 ± 0.004 0.015 ± 0.003 
a Cells were treated with different concentrations of the compounds for 72 h. Cell viability was 
measured by the MTT assay as described in the Experimental Section. 
b IC50 values are indicated as the mean ± SD (standard deviation) of at least three independent 
experiments. 
 
 Figure 3. Summarized SARs of the new synthesized compounds. 
Compound 24d Selectively Inhibited Cancer Cell Growth In Vitro. 
Nonselective cytotoxicity is one of the main factors limiting the clinical use of 
anticancer drugs.41 To obtain insights into the cytotoxic potential of these new 
compounds on normal human cells, the effects of compounds 24b, 24d, 29g, and 29l 
were evaluated in the normal human liver cell line L-O2 with CA-4 as the reference, 
which were compared with the IC50 values against human hepatocellular carcinoma 
cells (HepG2). As shown in Table 3, all the tested compounds showed high selectivity 
in inhibiting the growth of HepG2 cells vs. L-O2 cells with selective index (SI) values 
(IC50 of normal cells/IC50 of tumor cells) ranging from 24.1 to 65.8 while the SI value 
of the reference CA-4 was only 7.9. Importantly, the most potent compound in cancer 
cell antiproliferative assays, 24d, was the most selective with an SI value of 65.8. 
Thus, 24d was chosen for further biological studies. 
Table 3. Antiproliferative activities of compounds 24b, 24d, 29g, 29k and 29l against normal 
human liver cell line L-O2a. 
 
Compd. 
IC50 values (μM)b 
Selective Indexc 
HepG2 L-O2 
24b 0.036 ± 0.008 0.923 ± 0.056 25.6 
24d 0.015 ± 0.002 0.987 ± 0.064 65.8 
29g 0.027 ± 0.003 1.086 ± 0.101 40.2 
29k 0.038 ± 0.002 0.914 ± 0.091 24.1 
29l 0.024 ± 0.001 0.928 ± 0.082 38.7 
CA-4 0.012 ± 0.001 0.095 ± 0.012 7.9 
a Cells were treated with different concentrations of the compounds for 72 h. Cell viability was 
measured by an MTT assay as described in the Experimental Section. 
b IC50 values are indicated as the mean ± SD (standard deviation) of at least three independent 
experiments. 
c Selectivity index = (IC50 L-O2)/(IC50 HepG2). 
Compound 24d Inhibited Tubulin Polymerization and Colchicine Binding 
Effects. To investigate whether the antiproliferative activity of compound 24d was 
related to interactions with microtubule systems, 24d was evaluated for in vitro 
microtubule polymerization activity. The typical microtubule depolymerization agent 
(MDA) colchicine was employed as the reference. As shown in Figure 4, compound 
24d displayed a concentration-dependent inhibition of tubulin polymerization, 
indicating that the mechanism of 24d was consistent with colchicine as an MDA. 
Moreover, 24d exhibited more potent tubulin polymerization inhibitory activity (IC50 
= 1.71 μM) than CA-4 (IC50 = 2.53 μM) (Table 4). In addition, 24d competed with 
[3H]-colchicine in binding to tubulin. The binding potency of 24d to the colchicine 
binding site was comparable to that of CA-4 with the inhibition rates of 79.4% and 
92.7% at 1 μM and 5 μM, respectively (Table 4), indicating that 24d bound to the 
colchicine binding site similar to CA-4. 
  Compound 24d Disrupted the Organization of the Cellular Microtubule 
Network in K562 cells. The inhibitory effects of 24d on microtubule organization 
were further investigated by immunofluorescent staining in K562 cells. As shown in 
Figure 5, the microtubule networks in vehicle-treated cells had a normal arrangement 
with slim and fibrous microtubules wrapped around the cell nucleus. However, after 
exposure to 24d at three different concentrations (5 nM, 10 nM, and 20 nM) for 24 h, 
the microtubule organization in the cytosol were disrupted especially for the group 
that was treated with 24d at 30 nM, indicating that 24d induced disruption of the 
microtubule networks, which might eventually lead to cell apoptosis.  
Table 4. Inhibition of Tubulin Polymerizationa and Colchicine Binding to Tubulinb. 
Compd. 
Inhibition of tubulin polymerizaion  
Inhibition of colchicine binding 
(%) inhibition ± SD 
IC50 (μM) 1 μM 5 μM 
24d 1.71 ± 0.08 79.4 ± 4.4 92.7 ± 4.7 
CA-4 2.53 ± 0.19 81.2 ± 1.9 93.7 ± 4.4 
a The tubulin assembly assay measured the extent of assembly of 2 mg/mL tubulin after 60 min at 
37 °C. Data are presented as the mean ± SD from three independent experiments.  
b Tubulin, 1 μM; [3H]-colchicine, 5 μM; and inhibitors, 1 or 5 μM. 
  
Figure 4. Effect of 24d on tubulin polymerization in vitro. Purified tubulin protein at 2 mg/mL in 
a reaction buffer incubated at 37 °C in the presence of 1% DMSO, test compounds (24d at 1, 5, or 
10 μM) or colchicine (10 μM). Polymerizations were followed by an increase in fluorescence 
emission at 350 nm over a 60 min period at 37 °C. The experiments were performed three times. 
 
Figure 5. Effects of 24d on the cellular microtubule network visualized by immunofluorescence. 
K562 cells were treated with vehicle control 0.1% DMSO, 24d (5 nM, 10 nM, and 20 nM). Then, 
the cells were fixed and stained with anti-α-tubulin-FITC antibody (green), Alexa Fluor 488 dye 
and counterstained with DAPI (blue). The detection of the fixed and stained cells was performed 
with an LSM 570 laser confocal microscope (Carl Zeiss, Germany). 
Docking Studies of Compound 24d with Tubulin. To investigate the potential 
binding site of 24d with the tubulin-microtubule system, molecular modeling studies 
were performed. The crystal structure of tubulin complexed with CA-4 (PDB: 5lyj) 42 
was chosen as the docking protein. CA-4 was first redocked into the colchicine site 
with the resulting root mean square deviation (RMSD) value of 0.69 Å, which 
indicated our docking method was reasonable. As shown in Figure 6a, 24d adopted a 
very similar location with that of CA-4. The phenolic hydroxyl of 24d formed two 
hydrogen bonds with the residue Val 315 while the hydroxyl of CA-4 interacted with 
the residue Thr 179. The N-1 atom on the quinoline moiety of 24d formed a hydrogen 
bond with the critical residue Cys 241, which was similar to the binding pose of 
compound 11 with tubulin.33 The C-2 methyl group of 24d pointed towards the deep 
pocket of the colchicine site, which might explain how the C-2 position tolerated a 
modification without a significant decrease in activity. Similarly, the parent 
compound 1 was also docked into the colchicine site, and the result showed that 
compound 1 and 24d adopted similar positions when binding to tubulin (Figure 6b). 
The docking results demonstrated that 24d binds to the colchicine site of tubulin 
resembling the binding mode of CA-4. 
 Figure 6. Proposed binding models for 24d binding with tubulin (PDB code: 5lyj). (a) 
CA-4 (shown in yellow) and 24d (shown in cyan); (b) 1 (shown in pink) and 24d 
(shown in cyan). 
Compound 24d Induced G2/M Phase Arrest via Regulating G2/M-Related 
Protein Expression. Since most tubulin polymerization inhibitors could disrupt the 
regulated cell cycle distribution,43 a flow cytometry analysis was performed to 
examine the arrest effects of 24d on cell cycle of K562 cells. As illustrated in Figure 
7a and 7c, incubation with 24d arrested the cell cycle at the G2/M phase. The 
incubation of K562 cells with increasing concentrations of 24d from 0 to 30 nM 
increased the percentage of cells in the G2/M phase from 15.82% to 26.98%. 
  Mitosis in eukaryotic cells is regulated by the activation of Cdc2 kinase, which is 
controlled by several steps including cyclin B1 binding and cdc25c phosphorylation.44 
Thus, to obtain insight into the mechanism of 24d in K562 cell cycle arrest, the 
expression of cell cycle regulatory proteins was investigated. As shown in Figure 7b 
and 7d, 24d decreased cdc2, cyclin B1 and cdc25c protein levels in a 
concentration-dependent manner. The results suggested that the 24d-induced G2/M 
arrest may be correlated with a change of expression of cdc2/cyclin B1 and cdc25c. 
Compound 24d Induced Apoptosis via Regulating of Apoptosis-related Protein 
Expressions. Mitotic arrest of tumor cells by microtubule targeting agents is 
generally associated with cellular apoptosis. 45 Hoechst 33342 staining was first used 
to assess morphology changes of K562 cells, as shown in Figure 8a, K562 cells 
incubated with 24d (5, 10, and 20 nM) for 48 h displayed significant changes in cell 
morphology, such as nucleus fragmentation and chromatin condensation, indicating 
cell apoptosis. To further evaluate the capacity of 24d to induce apoptosis, 
Annexin-V/PI assay was performed with K562 cells. As shown in Figure 8b and 8d, 
after K562 cells were exposed to 5, 10, and 20 nM of 24d for 48 h, the total numbers 
of early (Annexin-V+/PI−) and late (Annexin-V+/PI+) apoptotic cells were 17.21%, 
34.55% and 60.14%, respectively. 
Increasing evidence has indicated that the regulation of the Bcl-2 family of proteins 
is involved in the signaling pathways,46 including pro-apoptotic (e.g., Bax and Bad) 
and anti-apoptotic proteins (e.g., Bcl-2 and Bcl-xl). As shown in Figure 8c and 8e, 
24d upregulated Bad and Bax and downregulated Bcl-2 and Bcl-xl protein levels in a 
concentration-dependent manner. Thus, as described above, compound 24d induced 
cell apoptosis by interfering with the expression of apoptosis-related proteins. 
 Figure 7. Compound 24d induced G2/M arrest in K562 cancer cells. (a) K562 cells were 
incubated with DMSO and varying concentrations of 24d (5, 10, and 20 nM) for 48 h. Cells were 
harvested and stained with PI and then analyzed by flow cytometry. The percentages of cells in 
different phases of the cell cycle were analyzed by ModFit 4.1. (b) Western blotting analysis on 
the effect of 24d on the G2/M regulatory proteins. The cells were harvested and lysed for the 
detection of cdc2, cdc25c and cyclin B1. (c) Histograms display the percentage of cell cycle 
distribution. (d) Histograms display the density ratios of cdc2, cdc25c and cyclin B1 to GADPH.  
  
Figure 8. Compound 24d induced apoptosis in K562 cancer cells. (a) Cell morphological 
alterations and nuclear changes (white arrow marked cells) associated with K562 cells after 
incubation with 24d (5, 10, and 20 nM) for 48 h were assessed by staining with Hoechst 33342 
and visualized by fluorescence microscopy; (b) K562 cells were incubated with DMSO and 
varying concentrations of 24d (5, 10, and 20 nM) for 48 h, cells were collected and stained with 
Annexin V/PI, followed by flow cytometric analysis; (c) Western blotting analysis on the effect of 
24d on apoptosis-related proteins. The cells were harvested and lysed to detect Bad, Bax, Bcl-2 
and Bcl-xl; (d) Histograms display the percentage of cell distribution; (e) Histograms display the 
density ratios of Bad, Bax, Bcl-2 and Bcl-xl to GADPH.  
Compound 24d Induced Mitochondrial Depolarization and Reactive Oxygen 
Species (ROS) Generation. Increasing evidence has indicated that mitochondria 
plays an important role in regulating cellular functions, and mitochondrial dysfunction 
is involved in many pathological processes.47 To explore whether 24d could induce 
mitochondrial dysfunction, mitochondrial membrane potential (MMP) assay by JC-1 
staining of mitochondria in K562 was performed. As shown in Figure 9a, with the 
concentrations of 24d increasing from 0 to 20 nM, the green fluorescence intensity 
(JC-1 monomers, low mitochondrial membrane potentials) correspondingly increased 
from 0.63% to 53.39%, suggesting that 24d caused MMP collapse of K562 cells and 
mitochondrial dysfunction, which eventually triggers apoptotic cell death. 
Accumulating evidence reveals that increased levels of reactive oxygen species 
(ROS) is often associated with promoting cancer cell growth,47 and mitochondrial 
membrane depolarization is related to mitochondrial production of ROS.48 Thus, the 
fluorescent probe 2′,7′-dichlorofluorescein diacetate (DCF-DA) was used to evaluate 
the intracellular ROS levels after incubation with 24d. As shown in Figure 9b and 9c, 
24d induced intracellular ROS generation with a dose-dependent manner, while the 
increased ROS was inhibited by pre-incubation with 2.5 mM of the ROS scavenger, 
N-acetyl cysteine (NAC).  
 Figure 9. Effects of 24d on the mitochondrial membrane potential of K562 cells. a) After 
incubation with different concentrations (0, 5, 10 and 20 nM) of 24d in K562 cells for 48 h prior 
to staining with JC-1 dye, the number of cells with collapsed mitochondrial membrane potentials 
was determined by flow cytometry analysis; (b) Histograms display the intracellular ROS contents 
in the absence or presence of 24d. **p < 0.01, ***p < 0.001 vs. control; ### p < 0.001 vs. 20 nM 
24d-treated group; (c) The generation of ROS was measured using the ROS-detecting fluorescent 
dye DCF-DA in combination with FACScan flow cytometry. 
  Compound 24d Inhibited the Migration and Invasion of MDA-MB-231 Cells. 
Cell migration and invasion play essential roles in achieving normal functions, such 
as wound healing and embryonic growth.49 Drugs that can simultaneously induce 
apoptosis and inhibit migration or invasion of cancer cells have clinical superiorities 
and have gained increasing research interest.50 To evaluate the ability of 24d in 
preventing the migration and invasion of cancer cells, transwell assays with or 
without Matrigel were conducted. The highly invasive and aggressive MDA-MB-231 
cell line was chosen for activity evaluation. As shown in Figure 10a and 10b, 24d 
dose-dependently inhibited MDA-MB-231 cell migration through the membrane of 
the transwell insert after incubation with 24d (2, 5, and 10 nM) for 48 h. In the 
invasion assay, 24d potently and dose-dependently inhibited cell invasion through the 
Matrigel-coated membrane (Figure 10c and 10d). These results indicated that 24d 
effectively inhibited the migration and invasion of MDA-MB-231 cells, which were 
not due to the cytotoxic actions of 24d (inhibitive rate under 10% after incubation 
with 24d at 10 nM for 48 h). 
 
Figure 10. Effects of 24d on transwell migration and invasion of MDA-MB-231 cells. (a) The 
MDA-MB-231 cells were seeded on chambers and incubated with 24d (0, 2, 5, and 10 nM) for 48 
h. Cells that migrated through the chambers were stained with crystal violet, and representative 
images were captured; (b) The cells that migrated through the chambers were counted from three 
independent experiments; (c) The MDA-MB-231 cells were seeded on chambers and and 
incubated with 24d (2, 5, and 10 nM) for 48 h. Cells that migrated through the Matrigel-coated 
chambers were stained with crystal violet, and representative images were captured; (d) The cells 
that migrated through the Matrigel-coated chambers were counted from three independent 
experiments. All the data in (b and d) were expressed as the means ± SD of each group of cells. 
**P < 0.01, ***P < 0.001 vs. control group. 
Compound 24d Exhibited Potent Anti-Vascular Activity. Most microtubule 
binding agents possess potent vascular disrupting activity, which are contributed to 
the disruption of microtubule dynamics to induce endothelial cell shape change.51 As 
HUVEC migration is the key step to generate new blood vessels, 52 wound healing 
assay was applied to assess the ability of 24d to inhibit HUVEC migration. As shown 
in Figure 11a and 11c, the untreated cells migrated to fill the area that was initially 
scraped after 24 h, while 24d significantly inhibited HUVEC migration at the dose of 
20 nM. 
We also evaluated the effect of 24d in a tube formation assay, which are based on 
the ability of HUVECs to form tubular and cord-like networks on Matrigel. In 
contrast to the tube-like networks of the control, the capillary-like tubes of HUVECs 
exposed to 24d at doses of 5, 10, and 20 nM for 6 h could be interrupted at different 
levels (Figure 11b). These results showed that 24d effectively inhibited the tube 
formation of HUVECs. 
The antiproliferative activity of 24d against HUVECs was also determined by an 
MTT assay to exclude the possibility that the anti-vascular activity of 24d was due to 
a cytotoxic action of 24d. The calculated IC50 value of 24d against HUVECs after a 
24-h treatment was 0.250 ± 0.06 μM, which is higher than the concentration of 10 nM 
required for the obvious inhibition of cell migration and tube formation. These results 
indicate that 24d exhibited possessed anti-vascular activity. 
Physicochemical Properties of 24d. To evaluate the drug-likeness of 24d, the 
physicochemical properties of 24d were predicted with compound 1 and CA-4 as the 
references.53 As shown in Table 5, compound 24d conformed to Lipinski’s rule of 
five. The aqueous solubility in phosphate buffer (pH 7.4) was also determined at 
20 °C by HPLC.54 As shown in Table 5, the solubility of 24d was approximately 5- 
and 16-fold greater than compounds 1 and CA-4, respectively. Moreover, the 
hydrochloride salt of 24d (24d-HCl) could be easily prepared by the reaction of 24d 
with hydrogen chloride in ethyl acetate, which was soluble in PBS (solubility > 1000 
μg/mL). The improvement of the aqueous solubility of 24d is most likely attributable 
to the quinoline moiety, which is more water-soluble than trimethylphenyl ring in 
compounds 1 and CA-4. 
Table 5. Aqueous Solubility in PBS (pH 7.4) and Physicochemical Properties of Compounds 1, 
CA-4, and 24d. 
Compd. MWa HBAb HBDc cLogPd tPSAe Solubility (μg/mL)f 
1 344.13 6 1 2.78 74.23 3.2 
CA-4 316.13 5 1 3.47 57.16 1.0 55 
24d 333.14 4 1 4.37 59.42 16.0 
24d-HCl - - - - - > 1000 
RO5g < 450 < 10 < 5 < 5 < 90 
 aMW: molecular weight; bHBA: hydrogen-bond acceptor atoms; cHBD: hydrogen-bond donor 
atoms; dclogP: calculated logarithm of the octanol-water partition coefficient; etPSA: topological 
polar surface area, calculated using http://www.molinspiration.com/cgi-bin/properties. fSolubility 
in PBS (pH 7.4); gRO5: Lipinski’s rule of five. 
 
Figure 11. Effects on HUVECs migration and tube formation. (a) Scratches were created with 
sterile 200 μL pipette tips, and images were captured using phase contrast microscopy at 0 h and 
24 h after treatments with 0, 5, 10 and 20 nM of 24d. (b) Images depicting the formation of a 
HUVEC capillary-like tubular network after treatments with 0, 5, 10 and 20 nM of 24d for 6 h. (c) 
Histograms display the length of the scratches at 0 h and 24 h after treatments with 0, 5, 10 and 20 
nM of 24d, ***P < 0.001 vs. control group. 
  The Safety Profile of 24d in Mice. To investigate the safety profiles of 24d, the 
acute toxicity was determined in ICR mice treated with 409.6, 512, 640, 800, and 
1000 mg/kg (iv, n = 10 per group) for 14 days. As shown in Table 6, treatment with 
24d at doses of 409.6 mg/kg only caused one death in ten mice, while treatment with 
24d at 1000 mg/kg killed nine mice. Finally, the median lethal dose (LD50) value of 
24d was calculated to be 665.62 mg/kg, indicating the low toxicity of 24d and its 
safety as an anti-tumor agent. 
Table 6. Acute Toxicity of 24d in Mice. 
dose (mg/kg) no. of mice total mortality survival (%) LD50 (mg/kg)
a 
409.6 10 1 90  
512 10 2 80  
640 10 4 60 665.62 
800 10 7 30  
1000 10 9 10  
a
The 95% confidence limits: 624.01−710.02 mg/kg. 
 
24d and 24d-HCl Inhibited the Growth of H22 Xenograft Tumors in Mice. The 
in vivo anti-tumor efficacy of 24d and 24d-HCl were further evaluated in mouse liver 
cancer xenograft models, which were established by subcutaneous inoculation of H22 
cells into the right flank of mice. Once the tumors were well-established, the mice 
were randomly allocated into eight groups: vehicle (iv, group 1), paclitaxel (PTX) (iv, 
8 mg/kg per 2 days, group 2), 24d (iv, 10 mg/kg per day, group 3), 24d (iv, 20 mg/kg 
per day, group 4), 24d-HCl (iv, 10 mg/kg per day, group 5), 24d-HCl (iv, 20 mg/kg 
per day, group 6), CA-4 (iv, 10 mg/kg per day, group 7), and CA-4 (iv, 20 mg/kg per 
day, group 8), with eight mice per group (Figure 12a). As shown in Figure 12b and 
12d, 24d and 24d-HCl significantly and dose-dependently decreased tumor volume 
and tumor weight. At the 20 mg/kg dose, 24d-HCl reduced the tumor weight by 
68.9%, which was more potent than the free drug 24d (65.3%). Although CA-4 
displayed comparable in vitro antiproliferative activity to 24d, its anti-tumor activity 
(inhibition rate: 55.3% at 20 mg/kg) was less potent than 24d. Additionally, PTX 
exhibited potent activity with an inhibition rate of 90.4% at a dose of 8 mg/kg every 2 
days. However, PTX-treated mice displayed significant decrease of body weight 
compared to those in control group (Figure 12c) while 24d and 24d-HCl did not 
obviously affect the body weight at doses of 10 and 20 mg/kg.  
Furthermore, we also observed the impact of 24d on tumor microvessels in vivo by 
immunohistochemistry. Tumor vessels were stained with CD31, which is a prominent 
endothelial marker that binds specifically to blood microvessels. As shown in Figure 
12e, 24d-treated group at the dose of 20 mg/kg displayed considerably lower tumor 
microvessel density (MVD) than the control group, indicating that 24d exhibited 
potent in vivo anti-vascular activity. 
Additionally, H&E staining of the heart, liver, spleen, lung and kidney collected at 
the end of the study also suggested no observable major organ-related toxicities 
(Figure 13). Overall, these data indicated that compound 24d was efficacious in 
inhibiting the growth of cancer in vivo with no observable toxicity. It deserves further 
evaluation as a safe anti-tumor agent. 
 
Figure 12. 24d inhibits liver cancer xenograft growth in vivo. After administering vehicle (group 
1), PTX (8 mg/kg per 2 days, group 2), 24d (10 mg/kg per day, group 3), 24d (20 mg/kg per day, 
group 4), 24d-HCl (10 mg/kg per day, group 5), 24d-HCl (20 mg/kg per day, group 6), CA-4 (10 
mg/kg per day, group 7), and CA-4 (20 mg/kg per day, group 8) for three weeks, the mice were 
sacrificed, and the tumors were weighed. (a) The images of tumors from mice at 21 days after 
initiation of treatment. (b) Tumor volume changes during treatment. (c) Body weight changes of 
mice during treatment. (d) The weight of the excised tumors of each group. ***P < 0.001 vs. 
control group. (e) Immunohistochemical staining against CD31 was used to quantify the 
microvessel density (MVD) in H22 xenograft tumors treated with vehicle and 24d (20 mg/kg). 
Representative images of anti-CD31 immunohistochemistry from five tumor xenografts are shown. 
**P < 0.01 vs. control group. 
 
Figure 13. HE staining of heart, liver, spleen, lung and kidney of mice. No abnormality of these 
organs was observed.  
CONCLUSION 
  Based on the previous work, we have continued to focus our studies on the new 
nitrogenous chalcones acting as CBSIs. With chalcone compound 1 as the parent 
compound, we designed and synthesized a series of novel quinoline-chalcone 
derivatives with comprehensive and detailed SARs. Some compounds displayed 
enhanced antiproliferative efficacy in a panel of human cancer cell lines, and the most 
potent compound 24d exhibited excellent antiproliferative activity with IC50 values 
ranging from 0.009 to 0.016 μM, which is comparable to those of the reference 
compound CA-4. Furthermore, 24d displayed a 65.8-fold selectivity ratio for normal 
human liver L-O2 cells, which was higher than that of CA-4, indicating that 24d 
might have lower toxicity than CA-4. 
  In addition, the microtubule polymerization inhibitory action of 24d was 
investigated using an in vitro tubulin polymerization assay, colchicine competition 
inhibition assay, immunofluorescence analysis of intracellular microtubules and a 
virtual molecular docking study. These experiments demonstrated that 24d effectively 
inhibited tubulin polymerization, and it bound to the colchicine site of tubulin. Further 
mechanistic studies indicated that 24d induced cell cycle arrest in the G2/M phase via 
regulation of G2/M-related protein expression (cdc2, cyclin B1, and cdc25c) and 
induced cell apoptosis by upregulating the expression of pro-apoptotic protein (Bad 
and Bax) and downregulating the expression of anti-apoptotic protein (Bcl-2 and 
Bcl-xl). Additionally, 24d depolarized the mitochondria membrane potentials and 
induced ROS generation in K562 cells. 
  Furthermore, 24d inhibited the migration and invasion of MDA-MB-231 cells in 
transwell migration and invasion assays, indicating the potent anti-metastatic activity 
of 24d. The anti-vascular activity of 24d was confirmed in in vitro HUVECs 
migration and tube formation assays, and in vivo microvessel formation in H22 
xenograft tumor issues. In addition, 24d displayed satisfactory physicochemical 
properties conforming to Lipinski’s rule of five, and its aqueous solubility was greatly 
improved compared with compound 1 and CA-4. More importantly, 24d have a safety 
profile with an LD50 value of 665.62 mg/kg after iv. injection, and 24d and 24d-HCl 
exhibited potent anti-tumor activities in mouse liver cancer xenograft models without 
observable major organ-related toxicities. 24d effectively suppressed the tumor 
volume and reduced tumor weight by 65.3% at 20 mg/kg per day (iv). In the 
meantime, the more water-soluble hydrochloride salt 24d-HCl displayed a higher 
inhibition rate of 68.9% at 20 mg/kg per day (iv), which is more potent than the 
reference CA-4. 
  Collectively, the new developed quinoline-chalcone derivative 24d has been shown 
to possess significant in vitro anti-metastatic activity, anti-vascular and anti-tumor 
activities both in vitro and in vivo. Thus, 24d has the potential to be further developed 
as an efficient chemotherapeutic agent. 
 
EXPERIMENTAL SECTION 
1. Chemistry.  
1.1 General Methods. All commercially available reagents were used without further 
purification. Solvents were dried through routine protocols. Flash column 
chromatography was carried out on 200-300 mesh silica gel (Qingdao Haiyang 
Chemical, China). Reactions were monitored by thin-layer chromatography (TLC) on 
0.25 mm silicagel plates (GF254) and visualized under UV light. 1H NMR and 13C 
NMR spectra were recorded with a Bruker AV-300 spectrometer (Bruker Company, 
Germany) in the indicated solvents (CDCl3 or DMSO-d6, TMS as internal standard): 
the values of the chemical shifts are expressed in δ values (ppm) and the coupling 
constants (J) in Hz. Low- and high-resolution mass spectra (LRMS and HRMS) were 
measured on Finnigan MAT 95 spectrometer (Finnigan, Germany). Purity of all tested 
compounds was ≥ 95%, as estimated by HPLC (SHIMADZU Labsolutions, UV 
dection at λ = 254 nm) analysis on the Aglilent C18 column (4.6 × 150 mm, 5 μm). 
1.2 1-(2-Methylquinolin-4-yl)ethan-1-one (16). 2-Methylquinoline-4-carboxylic 
acid (14) was synthesized according to literature report. 56 To a solution of 14 (500 mg, 
2.7 mmol) in 20 mL anhydrous CH2Cl2 was added dimethylamine hydrochloride (310 
mg, 3.2 mmol), trimethylamine (440 μL, 3.2 mmol), EDCI (1.0 g, 5.4 mmol), HOBt 
(437.4 mg, 3.2 mmol) and catalytic amount of DMAP. The mixture was stirred for 2 h, 
and extracted with CH2Cl2 (3 × 50 mL). The combined organic layers were then 
washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to afford 
15 as a yellow solid (510 mg, yield 83.1%), which was used for next step without 
further purification. A solution of CH3MgBr in diethyl ether (3 M, 2.0 mL, 5.9 mmol) 
was added dropwise to a solution of 15 (500 mg, 2.7 mmol) in 20 mL anhydrous THF 
under nitrogen atmosphere at 0 °C. After stirring for 2 h, the reaction was quenched 
by NH4Cl aqueous, and extracted with CH2Cl2 (3 × 50 mL). The combined organic 
layers were then washed with brine, dried over anhydrous Na2SO4, and concentrated 
in vacuo to provide the crude product, which was purified by column chromatography 
with petroleum/ethyl acetate (2:1) to give 16 (420 mg, 84.0 %); 1H NMR (300 MHz, 
CDCl3) δ 8.39 - 8.31 (m, 1H), 8.09 - 8.00 (m, 1H), 7.76 - 7.65 (m, 1H), 7.58 - 7.51 (m, 
1H), 7.47 (s, 1H), 2.78 (s, 3H), 2.71 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 201.38, 
158.40, 148.87, 143.07, 129.81, 129.16, 127.27, 125.22, 121.91, 120.70, 30.04, 25.34; 
ESI-MS m/z [M+Na]+ 208.1. 
1.3 2-Methylquinoline-4-carbaldehyde (19). Intermediate 18 was synthesized 
according to literature report.40 To a solution of 18 (15.0 g, 86.7 mmol) in 50 mL 
CH2Cl2 was added Dess-Martin reagent (40.4 g, 95.3 mmol) in batches. The mixture 
was stirred for 2 h, and quenched by Na2S2O4 aqueous. The residue was extracted 
with EtOAc (3 × 50 mL), and the combined organic layers were then washed with 
saturated NaHCO3, brine, dried over anhydrous Na2SO4, and concentrated in vacuo to 
afford the crude product, which was purified by column chromatography with 
petroleum/ethyl acetate (2:1) to give 19 (12 g, 80.0 %); 1H NMR (300 MHz, CDCl3) δ 
10.42 (s, 1H), 8.91 (d, J = 8.4 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.80 - 7.71 (m, 1H), 
7.62 (d, J = 4.3 Hz, 2H), 2.83 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 192.92, 159.09, 
148.96, 136.96, 130.08, 129.15, 128.24, 127.06, 124.18, 122.15, 25.22; ESI-MS m/z  
[M+Na]+ 194.1. 
1.4 1-(2-Methylquinolin-4-yl)propan-1-one (21). A solution of C2H5MgBr in 
diethyl ether (3 M, 12 mL, 36.0 mmol) was added dropwise to a solution of 19 (5.0 g, 
29.1 mmol) in 50 mL anhydrous THF under nitrogen atmosphere at 0 °C. After 
stirring for 2 h, the reaction was quenched by NH4Cl aqueous, and extracted with 
CH2Cl2 (3 × 50 mL). The combined organic layers were then washed with brine, dried 
over anhydrous Na2SO4, and concentrated in vacuo to provide the crude product, 
which was purified by column chromatography with petroleum/ethyl acetate (2:1) to 
give intermediate 20 (4.3 g, 74.1 %). To a solution of 20 (2.0 g, 9.95 mmol) in 50 mL 
CH2Cl2 was added Dess-Martin reagent (5.1 g, 11.9 mmol) in batches. The mixture 
was stirred for 2 h, and quenched by Na2S2O4 aqueous. The residue extracted with 
EtOAc (3 × 50 mL), and the combined organic layers were then washed with 
saturated NaHCO3, brine, dried over anhydrous Na2SO4, and concentrated in vacuo to 
afford the crude product, which was purified by column chromatography with 
petroleum/ethyl acetate (2:1) to give 21 (1.3 g, 65.1%). 1H NMR (300 MHz, CDCl3) δ 
8.16 (d, J = 8.5 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.73 - 7.65 (m, 1H), 7.55 - 7.48 (m, 
1H), 7.38 (s, 1H), 3.01 (q, J = 7.5 Hz, 2H), 2.76 (s, 3H), 1.25 (t, J = 7.2 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 158.38, 148.70, 144.14, 136.94, 129.85, 129.15, 127.08, 
125.05, 122.09, 119.70, 35.85, 25.38, 8.05; ESI-MS m/z [M+Na]+ 222.1. 
1.5 General procedures for the preparation of 24a and 24b. To a solution of 16 
(75 mg, 0.40 mmol) or 21 (80 mg, 0.40 mmol) in 5 mL EtOH was added NaOH (81 
mg, 2.0 mmol). After stirring for 5 min, 3-nitro-4-methoxybenzaldehyde (88 mg, 0.49 
mmol) was added in one portion. After reaction completed, the mixture was extracted 
with EtOAc (3 × 20 mL), and the combined organic layers were then washed with 
saturated brine, dried over anhydrous Na2SO4, and concentrated in vacuo to afford the 
crude products. The crude products were dissolved into the mixture solvent of 5 mL 
EtOH and 5 mL AcOH, Fe powder (77 mg, 1.38 mmol) was added, and the mixture 
was stirred at 65 °C for 30 min. Then, the solvent was removed in vacuo, and the 
residue was neutralized by saturated NaHCO3 aqueous. The mixture was filtrated, and 
the filtrates was extracted with EtOAc (3 × 20 mL), and the combined organic layers 
were then washed with saturated brine, dried over anhydrous Na2SO4, and 
concentrated in vacuo to afford the crude products, which was purified by column 
chromatography with petroleum/ethyl acetate (2:1) to give 24a or 24b. 
(E)-3-(3-amino-4-methoxyphenyl)-1-(2-methylquinolin-4-yl)prop-2-en-1-one 
(24a). Yellow solid (54 mg, yield 42.5% over two steps).1H NMR (300 MHz, CDCl3) 
δ 8.07 (d, J = 8.5 Hz, 1H), 8.03 - 7.95 (m, 1H), 7.70 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 
7.51 - 7.45 (m, 1H), 7.37 (d, J = 17.0 Hz, 2H), 7.00 (d, J = 16.0 Hz, 1H), 6.94 - 6.85 
(m, 2H), 6.75 (d, J = 8.2 Hz, 1H), 3.86 (s, 3H), 2.78 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 195.10, 158.43, 150.23, 148.66, 148.41, 145.59, 136.80, 129.86, 129.10, 
127.11, 126.66, 125.24, 124.00, 123.01, 121.40, 119.94, 113.21, 110.21, 77.47, 77.05, 
76.63, 55.62, 25.42; HR-MS (ESI) m/z: calcd for C21H21N2O2 [M+H]
+ 319.1441, 
found 319.1445; Purity: 95.2% (by HPLC). 
(E)-3-(3-amino-4-methoxyphenyl)-2-methyl-1-(2-methylquinolin-4-yl)prop-2-e
n-1-one (24b). Yellow solid (65 mg, yield 50.4% over two steps). 1H NMR (300 MHz, 
CDCl3) δ 8.00 (d, J = 8.5 Hz, 1H), 7.64 (m, 2H), 7.39 (t, J = 7.4 Hz, 1H), 7.17 (d, J = 
9.8 Hz, 1H), 6.97 (s, 1H), 6.84 - 6.56 (m, 3H), 3.79 (s, 3H), 2.70 (s, 3H), 2.28 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 198.29, 157.71, 148.04, 147.56, 147.05, 146.18, 135.72, 
134.76, 129.35, 128.50, 127.69, 125.95, 124.78, 123.32, 121.43, 119.44, 115.79, 
109.56, 55.05, 29.17, 24.83; HR-MS (ESI) m/z: calcd for C21H21N2O2 [M+H]
+ 
333.1598, found 333.1604. Purity: 98.2% (by HPLC). 
1.6 General procedures for the preparation of 24c and 24d. To a solution of 16 (75 
mg, 0.40 mmol) or 21 (80 mg, 0.40 mmol) in 5 mL EtOH was added NaOH (81 mg, 
2.0 mmol). After stirring for 5 min, MEM protected isovanillin (117 mg, 0.49 mmol) 
was added in one portion. After reaction completed, the mixture was extracted with 
EtOAc (3 × 20 mL), and the combined organic layers were then washed with 
saturated brine, dried over anhydrous Na2SO4, and concentrated in vacuo to afford the 
crude products, which was purified by column chromatography with petroleum/ethyl 
acetate (4:1) to give products as colorless oil. Then, the products were dissolved in 5 
mL EtOH, 1 mL 10% HCl aqueous was added followed by refluxing for 30 min. Then, 
the mixture was extracted with EtOAc (3 × 20 mL), and the combined organic layers 
were then washed with saturated brine, dried over anhydrous Na2SO4, and 
concentrated in vacuo to afford the crude products, which was purified by column 
chromatography with petroleum/ethyl acetate (2:1) to give products 24c or 24d. 
(E)-3-(3-hydroxy-4-methoxyphenyl)-1-(2-methylquinolin-4-yl)prop-2-en-1-one 
(24c). Yellow solid (65 mg, 50.3% over two steps). 1H NMR (300 MHz, DMSO-d6) δ 
9.26 (s, 1H), 8.03 (d, J = 9.0 Hz, 2H), 7.76 (t, J = 7.6 Hz, 1H), 7.65 (s, 1H), 7.57 (t, J 
= 7.9 Hz, 1H), 7.50 (d, J = 16.0 Hz, 1H), 7.33 - 7.22 (m, 2H), 7.20 (d, J = 6.3 Hz, 1H), 
6.97 (d, J = 8.4 Hz, 1H), 3.83 (s, 3H), 2.74 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 
193.80, 158.59, 150.87, 147.82, 147.55, 146.77, 144.27, 129.66, 128.80, 126.94, 
126.61, 124.96, 123.60, 122.60, 122.37, 120.42, 114.68, 111.91, 55.65, 24.81; HR-MS 
(ESI) m/z: calcd for C20H18NO3 [M+H]
+ 320.1281, found 320.1285. Purity: 95.8% (by 
HPLC). 
(E)-3-(3-hydroxy-4-methoxyphenyl)-2-methyl-1-(2-methylquinolin-4-yl)prop-2
-en-1-one (24d). Yellow solid (52 mg, 36.1% over two steps). 1H NMR (300 MHz, 
CDCl3) δ 8.08 (d, J = 8.5 Hz, 1H), 7.76 - 7.67 (m 2H), 7.47 (t, J = 7.6 Hz, 1H), 7.24 (s, 
1H), 7.12 - 6.99 (m, 2H), 6.94 - 6.78 (m, 2H), 3.89 (s, 3H), 2.77 (s, 3H), 2.35 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 198.19, 157.71, 147.54, 147.44, 146.36, 146.11, 145.21, 
135.33, 129.44, 128.39, 128.07, 126.03, 124.75, 123.30, 123.06, 119.50, 115.76, 
110.05, 76.94, 76.52, 76.10, 55.45, 24.71, 12.31; HR-MS (ESI) m/z: calcd for 
C21H20NO3 [M+H]
+ 334.1438, found 334.1446. Purity: 99.3% (by HPLC). 
1.7 General procedures for the preparation of 24e-h. To a solution of 16 (75 mg, 
0.40 mmol) or 21 (80 mg, 0.40 mmol) in 5 mL EtOH was added NaOH (81 mg, 2.0 
mmol). After stirring for 5 min, various benzaldehydes (0.49 mmol) was added in one 
portion. After reaction completed, the mixture was extracted with EtOAc (3 × 20 mL), 
and the combined organic layers were then washed with saturated brine, dried over 
anhydrous Na2SO4, and concentrated in vacuo to afford the crude products, which was 
purified by column chromatography with petroleum/ethyl acetate (2:1) to give 24e-h. 
(E)-3-(4-methoxyphenyl)-2-methyl-1-(2-methylquinolin-4-yl)prop-2-en-1-one 
(24e). White solid (82 mg, 64.4%). 1H NMR (300 MHz, CDCl3) δ 8.03 - 7.97 (m, 1H), 
7.70 - 7.59 (m, 2H), 7.39 (m, 1H), 7.28 (s, 1H), 7.25 (s, 1H), 7.17 (s, 1H), 7.06 - 7.02 
(m, 1H), 6.82 (d, J = 8.9 Hz, 2H), 3.74 (s, 3H), 2.71 (s, 3H), 2.29 (s, 3H).; 13C NMR 
(75 MHz, CDCl3) δ 198.20, 160.17, 157.71, 147.59, 146.21, 146.01, 134.96, 131.64, 
129.37, 128.55, 127.27, 125.97, 124.73, 123.28, 119.42, 113.59, 54.85, 24.86, 12.35; 
HR-MS (ESI) m/z: calcd for C21H20NO2 [M+H]
+ 318.1489, found 318.1494. Purity: 
99.8% (by HPLC). 
(E)-3-(3,4-dimethoxyphenyl)-2-methyl-1-(2-methylquinolin-4-yl)prop-2-en-1-o
ne (24f). White solid (91 mg, 65.2%). 1H NMR (300 MHz, CDCl3) δ 8.04 - 7.97 (m, 
1H), 7.70 - 7.59 (m, 2H), 7.44 - 7.36 (m, 1H), 7.18 (d, J = 7.1 Hz, 1H), 7.03 (d, J = 
1.5 Hz, 1H), 6.95 (dd, J = 8.5, 2.0 Hz, 1H), 6.79 (dd, J = 5.3, 3.2 Hz, 2H), 3.82 (s, 
3H), 3.76 (s, 3H), 2.70 (s, 3H), 2.31 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 198.68, 
158.25, 150.30, 148.75, 148.08, 146.94, 146.46, 135.66, 129.94, 129.02, 127.97, 
126.53, 125.24, 124.13, 123.76, 119.93, 113.20, 110.88, 55.95, 25.42, 12.95; HR-MS 
(ESI) m/z: calcd for C22H12NO3 [M+H]
+ 348.1594, found 348.1596. Purity: 99.6% (by 
HPLC). 
(E)-3-(3-fluoro-4-methoxyphenyl)-2-methyl-1-(2-methylquinolin-4-yl)prop-2-e
n-1-one (24g). White solid (78 mg, 57.9%). 1H NMR (300 MHz, CDCl3) δ 8.08 (d, J 
= 8.5 Hz, 1H), 7.77 - 7.66 (m, 2H), 7.48 (m, 1H), 7.24 (s, 1H), 7.19 (dd, J = 12.4, 2.2 
Hz, 1H), 7.10 - 7.03 (m, 2H), 6.93 (t, J = 8.5 Hz, 1H), 3.90 (s, 3H), 2.78 (s, 3H), 2.35 
(s, 3H); 13C NMR (75 MHz, CDCl3) δ 198.01, 157.71, 147.62, 145.60, 144.66, 136.07, 
129.42, 128.63, 127.71, 126.81, 126.04, 124.60, 123.17, 121.85, 119.42, 117.15, 
116.90, 112.56, 55.73, 24.86, 12.31; HR-MS (ESI) m/z: calcd for C21H19FNO2 
[M+H]+ 336.1394, found 336.1396. Purity: 95.1% (by HPLC). 
(E)-2-methyl-1-(2-methylquinolin-4-yl)-3-(4-(methylthio)phenyl)prop-2-en-1-o
ne (24h). White solid (83 mg, 62.0%). 1H NMR (300 MHz, CDCl3) δ 8.08 (d, J = 8.4 
Hz, 1H), 7.79 - 7.66 (m, 2H), 7.49 (dd, J = 11.2, 4.0 Hz, 1H), 7.30 - 7.19 (m, 5H), 
7.11 (s, 1H), 2.78 (s, 3H), 2.48 (s, 3H), 2.36 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
198.72, 158.25, 148.09, 146.29, 146.24, 141.39, 136.77, 131.48, 130.62, 129.97, 
129.08, 127.61, 126.80, 126.57, 125.59, 125.18, 123.72, 120.00, 25.40, 15.06, 12.99; 
HR-MS (ESI) m/z: calcd for C21H20NOS [M+H]
+ 334.1260, found 334.1259. Purity: 
98.2% (by HPLC). 
1.8 General procedures for the preparation of 24i-o. To a solution of 16 (75 mg, 
0.40 mmol) or 21 (80 mg, 0.40 mmol) in 5 mL EtOH, piperidine (48 μL, 0.48 mmol) 
and indole formaldehydes (0.48 mmol) were added. After the mixture was stirred at 
95 °C for 48 h. After reaction completed, the mixture was extracted with EtOAc (3 × 
20 mL), and the combined organic layers were then washed with saturated brine, 
dried over anhydrous Na2SO4, and concentrated in vacuo to afford the crude products, 
which was purified by column chromatography with petroleum/ethyl acetate (2:1) to 
give 24i-o. 
(E)-3-(1H-indol-4-yl)-1-(2-methylquinolin-4-yl)prop-2-en-1-one (24i). Yellow 
solid (74 mg, 54.9%). 1H NMR (300 MHz, CDCl3) δ 9.11 (s, 1H), 8.11 (dd, J = 8.2, 
4.6 Hz, 2H), 7.97 (d, J = 16.1 Hz, 1H), 7.78 - 7.66 (m, 1H), 7.53 (d, J = 7.1 Hz, 1H), 
7.48 (d, J = 3.4 Hz, 1H), 7.44 (m, 2H), 7.38 (s, 1H), 7.35 - 7.27 (m, 1H), 7.19 (t, J = 
7.8 Hz, 1H), 6.74 (s, 1H), 2.81 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 194.81, 157.99, 
150.12, 147.86, 145.39, 137.27, 129.45, 128.47, 127.86, 126.21, 125.54, 125.26, 
124.82, 123.19, 122.63, 121.49, 119.49, 111.40, 103.12, 76.96, 76.54, 76.12, 24.83; 
HR-MS (ESI) m/z: calcd for C21H17N2O [M+H]
+ 313.1335, found 313.1333. Purity: 
97.2% (by HPLC). 
(E)-3-(1H-indol-4-yl)-2-methyl-1-(2-methylquinolin-4-yl)prop-2-en-1-one (24j). 
Yellow solid (69 mg, 51.1%). 1H NMR (300 MHz, CDCl3) δ 8.71 (s, 1H), 8.02 (d, J = 
8.4 Hz, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.63 (t, J = 7.1 Hz, 1H), 7.55 (s, 1H), 7.42 (t, J 
= 7.4 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.26 (s, 1H), 7.22 (d, J = 7.3 Hz, 1H), 7.14 
(dd, J = 13.3, 5.6 Hz, 1H), 7.08 - 7.01 (m, 1H), 5.94 (s, 1H), 2.71 (s, 3H), 2.31 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 198.58, 157.80, 147.58, 146.13, 144.91, 136.89, 135.29, 
129.49, 128.49, 127.27, 126.53, 126.08, 124.90, 124.67, 123.37, 121.20, 120.48, 
119.68, 112.13, 100.22, 24.81, 12.79; HR-MS (ESI) m/z: calcd for C22H19N2O 
[M+H]+ 327.1492, found 327.1498. Purity: 96.6% (by HPLC). 
(E)-3-(1H-indol-5-yl)-1-(2-methylquinolin-4-yl)prop-2-en-1-one (24k). Yellow 
solid (72 mg, 53.4%). 1H NMR (300 MHz, CDCl3) δ 8.87 (s, 1H), 8.02 (d, J = 8.5 Hz, 
1H), 7.96 (d, J = 8.4 Hz, 1H), 7.72 (s, 1H), 7.66 - 7.56 (m, 2H), 7.43 (d, J = 7.4 Hz, 
1H), 7.36 (m, 3H), 7.18 - 7.08 (m, 2H), 6.48 (s, 1H), 2.72 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 194.83, 158.00, 150.13, 147.88, 145.41, 137.28, 129.46, 128.48, 127.87, 
126.23, 125.55, 125.27, 124.83, 123.20, 122.64, 121.50, 119.50, 111.41, 103.13, 
24.83; HR-MS (ESI) m/z: calcd for C21H17N2O [M+H]
+ 313.1335 found 313.1339. 
Purity: 96.4% (by HPLC). 
(E)-3-(1H-indol-5-yl)-2-methyl-1-(2-methylquinolin-4-yl)prop-2-en-1-one (24l). 
Yellow solid (65 mg, 49.6%). 1H NMR (300 MHz, CDCl3) δ 8.98 (s, 1H), 8.09 (d, J = 
8.4 Hz, 1H), 7.79 (d, J = 8.3 Hz, 1H), 7.72 (s, 1H), 7.67 (d, J = 7.2 Hz, 1H), 7.46 (t, J 
= 7.2 Hz, 1H), 7.38 - 7.24 (m, 3H), 7.19 (d, J = 7.6 Hz, 2H), 6.54 (s, 1H), 2.78 (s, 3H), 
2.45 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 198.53, 157.80, 148.99, 147.57, 146.47, 
135.92, 134.36, 129.44, 128.41, 127.60, 126.46, 126.03, 125.11, 124.89, 124.17, 
123.43, 123.37, 119.52, 110.76, 102.84, 24.81, 12.51; HR-MS (ESI) m/z: calcd for 
C22H19N2O [M+H]
+ 327.1492, found 327.1497. Purity: 95.1% (by HPLC). 
(E)-2-methyl-3-(1-methyl-1H-indol-5-yl)-1-(2-methylquinolin-4-yl)prop-2-en-1-
one (24m). Yellow solid (78 mg, 57.1%). 1H NMR (300 MHz, CDCl3) δ 7.98 (d, J = 
8.5 Hz, 1H), 7.72 - 7.65 (m, 1H), 7.62 - 7.53 (m, 2H), 7.35 (td, J = 7.0, 3.5 Hz, 1H), 
7.24 (s, 1H), 7.19 - 7.09 (m, 3H), 6.93 (d, J = 3.1 Hz, 1H), 6.37 (d, J = 3.1 Hz, 1H), 
3.62 (s, 3H), 2.67 (s, 3H), 2.38 - 2.30 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 198.88, 
158.25, 149.37, 148.12, 146.89, 137.11, 134.75, 130.19, 129.83, 129.05, 128.55, 
126.52, 126.43, 125.39, 124.32, 124.07, 123.91, 119.98, 109.37, 102.05, 32.93, 25.43, 
13.06; HR-MS (ESI) m/z: calcd for C23H21N2O [M+H]
+ 341.1648, found 341.1654. 
Purity: 97.1% (by HPLC). 
 (E)-3-(6-methoxy-1H-indol-3-yl)-1-(2-methylquinolin-4-yl)prop-2-en-1-one 
(24n). Yellow solid (65 mg, 46.9%). 1H NMR (300 MHz, DMSO-d6) δ 8.04 (s, 1H), 
8.01 (s, 2H), 7.81 (d, J = 15.8 Hz, 1H), 7.75 (d, J = 7.2 Hz, 1H), 7.63 -7.52 (m, 2H), 
7.41 (d, J = 9.1 Hz, 2H), 7.18 (d, J = 16.0 Hz, 1H), 6.90 (dd, J = 8.7, 2.1 Hz, 1H), 
3.83 (s, 3H), 2.75 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 193.73, 158.57, 155.16, 
147.78, 145.56, 142.60, 134.44, 132.52, 129.60, 128.75, 126.37, 125.67, 125.14, 
122.73, 119.95, 119.67, 113.32, 112.42, 112.17, 102.59, 55.53, 24.85; HR-MS (ESI) 
m/z: calcd for C22H19N2O2 [M+H]
+ 343.1441, found 343.1444. Purity: 96.0% (by 
HPLC). 
(E)-3-(6-methoxy-1H-indol-3-yl)-2-methyl-1-(2-methylquinolin-4-yl)prop-2-en-
1-one (24o). Yellow solid (59 mg, 41.2%). 1H NMR (300 MHz, DMSO-d6) δ 11.88 (s, 
1H), 8.04 (d, J = 8.4 Hz, 1H), 7.88 (s, 1H), 7.81 - 7.67 (m, 2H), 7.52 (td, J = 6.8, 3.3 
Hz, 1H), 7.44 (d, J = 6.9 Hz, 2H), 6.99 - 6.90 (m, 2H), 6.64 (dd, J = 8.7, 2.3 Hz, 1H), 
3.74 (s, 3H), 2.74 (s, 3H), 2.31 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 196.21, 
158.25, 156.37, 147.41, 146.46, 138.33, 136.59, 130.38, 129.65, 128.77, 126.23, 
125.11, 123.39, 121.06, 119.69, 118.10, 118.09, 111.33, 110.72, 94.96, 55.15, 40.34, 
40.06, 39.79, 39.51, 39.23, 38.95, 38.67, 24.85, 13.16; HR-MS (ESI) m/z: calcd for 
C23H21N2O2 [M+H]
+ 357.1598, found 357.1595. Purity: 97.5% (by HPLC). 
1.9 1-(2-(Hydroxymethyl)quinolin-4-yl)propan-1-one (28). To a solution of 21 (300 
mg, 1.52 mmol) in 15 mL anhydrous CH2Cl2 was added m-CPBA (75%, 450 mg, 1.98 
mmol) in one portion. The mixture was stirred for 2 h at ambient temperature. Then, 
the reaction was quenched by Na2S2O4 aqueous. The residue was extracted with 
EtOAc (3 × 20 mL), and the combined organic layers were then washed with 
saturated NaHCO3, brine, dried over anhydrous Na2SO4, and concentrated in vacuo to 
afford the crude product 27. 27 was then dissolved in 20 mL Ac2O, and the mixture 
was stirred at refluxing temperature for 2 h. After reaction completion, Ac2O was 
removed in vacuo, and the residue was dissolved in 5 mL CH3OH followed by the 
addition of ammonia in CH3OH. After stirring for 30 min, solvent was removed in 
vacuo to afford the crude produce 28, which was purified by column chromatography 
with petroleum/ethyl acetate (2:1) to give 28 as a yellow solid (200 mg, yield 67.9% 
over three steps).  
1.10 General procedures for the preparation of 29a and 29c-n. The synthesis of 
29a and 29c-n referred to the general procedures for the preparation of 24c and 24d.   
(E)-3-(3-hydroxy-4-methoxyphenyl)-1-(2-(hydroxymethyl)quinolin-4-yl)-2-met
hylprop-2-en-1-one (29a). Yellow solid (61 mg, 43.7% over two steps). 1H NMR 
(300 MHz, CDCl3) δ 8.07 (d, J = 8.5 Hz, 1H), 7.69 (dd, J = 12.7, 8.4 Hz, 2H), 7.51 - 
7.42 (m, 1H), 7.20 (d, J = 1.5 Hz, 1H), 6.97 (s, 2H), 6.75 (d, J = 8.7 Hz, 2H), 4.88 (s, 
2H), 4.69 (s, 1H), 3.83 (s, 3H), 2.29 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 198.49, 
158.39, 147.89, 147.17, 147.08, 145.54, 135.77, 130.31, 129.04, 128.46, 127.19, 
125.49, 124.95, 124.02, 123.80, 116.48, 116.09, 110.42, 64.26, 55.98, 29.70; HR-MS 
(ESI) m/z: calcd for C21H20NO4 [M+H]
+ 350.1387, found 350.1381. Purity: 95.4% (by 
HPLC). 
(E)-4-(3-(3-hydroxy-4-methoxyphenyl)-2-methylacryloyl)quinoline-2-carbalde
hyde (29b). To a solution of 29a (30 mg, 0.08 mmol) in 2 mL DMSO was added IBX 
(29 mg, 0.10 mmol). The reactions were stirred for 30 min, then the mixtures were 
diluted with 50 mL EtOAc, then washed with water (20 mL × 3), saturated brine, 
dried over anhydrous Na2SO4, and concentrated in vacuo to afford crude products, 
which was purified by column chromatography with petroleum/ethyl acetate (2:1) to 
give 29b as yellow solid (26 mg, 74.9%). 1H NMR (300 MHz, CDCl3) δ 10.18 (s, 1H), 
8.25 (d, J = 8.4 Hz, 1H), 7.90 (s, 1H), 7.86 - 7.73 (m, 2H), 7.62 (dd, J = 11.2, 4.1 Hz, 
1H), 6.95 (s, 2H), 6.77 - 6.72 (m, 2H), 5.71 (s, 1H), 3.82 (s, 3H), 2.30 (s, 3H)；13C 
NMR (75 MHz, CDCl3) δ 197.83, 193.27, 151.69, 148.23, 147.93, 147.63, 147.40, 
145.51, 135.73, 130.92, 130.88, 130.06, 128.35, 127.37, 125.71, 123.87, 116.10, 
115.47, 110.40, 55.97, 29.70; HR-MS (ESI) m/z: calcd for C21H18NO4 [M+H]
+ 
348.1230, found 348.1232. Purity: 97.8% (by HPLC). 
(E)-1-(2-chloroquinolin-4-yl)-3-(3-hydroxy-4-methoxyphenyl)-2-methylprop-2-
en-1-one (29c). White solid (65 mg, 45.9% over two steps). 1H NMR (300 MHz, 
CDCl3) δ 8.01 (d, J = 8.4 Hz, 1H), 7.78 - 7.63 (m, 2H), 7.48 (t, J = 7.6 Hz, 1H), 7.28 
(s, 1H), 7.00 (s, 2H), 6.86 - 6.72 (m, 2H), 5.67 (s, 1H), 3.84 (s, 3H), 2.29 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 196.88, 149.93, 149.39, 148.15, 148.00, 147.59, 145.54, 
135.55, 131.07, 129.01, 128.31, 127.74, 125.49, 124.36, 124.01, 120.21, 116.07, 
110.42, 56.00, 29.70; HR-MS (ESI) m/z: calcd for C20H17ClNO3 [M+H]
+ 354.0891, 
found 327.0895. Purity: 95.8% (by HPLC). 
(E)-1-(2-(dimethylamino)quinolin-4-yl)-3-(3-hydroxy-4-methoxyphenyl)-2-met
hylprop-2-en-1-one (29d). Yellow solid (82 mg, 56.6% over two steps). 1H NMR 
(300 MHz, DMSO-d6) δ 9.16 (s, 1H), 7.53 (d, J = 8.1 Hz, 1H), 7.49 - 7.36 (m, 1H), 
7.32 (d, J = 7.9 Hz, 1H), 7.07 (d, J = 7.3 Hz, 1H), 7.02 (s, 1H), 6.96 (s, 1H), 6.90 (s, 
1H), 6.82 (dd, J = 16.2, 8.1 Hz, 2H), 3.69 (s, 3H), 3.08 (s, 6H), 2.17 (s, 3H); 13C NMR 
(75 MHz, DMSO-d6) δ 198.74, 156.79, 149.64, 148.20, 147.51, 146.81, 146.47, 
134.80, 130.14, 128.04, 126.84, 125.25, 123.62, 122.32, 119.77, 117.40, 112.34, 
107.92, 56.01, 38.13, 13.07; HR-MS (ESI) m/z: calcd for C22H23N2O3 [M+H]
+ 
363.1703, found 363.1706. Purity: 96.4% (by HPLC). 
(E)-3-(3-hydroxy-4-methoxyphenyl)-2-methyl-1-(2-(pyrrolidin-1-yl)quinolin-4-
yl)prop-2-en-1-one (29e). Yellow solid (88 mg, 56.6% over two steps). 1H NMR 
(300 MHz, CDCl3) δ 7.76 (d, J = 8.5 Hz, 1H), 7.61 - 7.49 (m, 2H), 7.18 (s, 1H), 7.16 - 
7.07 (m, 1H), 7.05 (s, 1H), 6.85 (q, J = 8.2 Hz, 2H), 6.66 (s, 1H), 3.89 (s, 3H), 3.62 (s, 
4H), 2.32 (s, 3H), 2.03 (s, 4H); 13C NMR (75 MHz, CDCl3) δ 199.38, 154.69, 148.62, 
147.99, 147.51, 146.68, 145.65, 135.59, 129.97, 128.67, 126.23, 125.28, 123.65, 
121.95, 119.99, 116.25, 110.52, 108.61, 55.94, 47.00, 25.53, 12.79; HR-MS (ESI) m/z: 
calcd for C24H25N2O3 [M+H]
+ 389.1860, found 389.1868. Purity: 99.4% (by HPLC). 
(E)-3-(3-hydroxy-4-methoxyphenyl)-2-methyl-1-(2-morpholinoquinolin-4-yl)pr
op-2-en-1-one (29f). Yellow solid (98 mg, 60.6% over two steps). 1H NMR (300 
MHz, CDCl3) δ 7.76 (d, J = 8.3 Hz, 1H), 7.59 -7.53 (m, 2H), 7.22 (t, J = 7.5 Hz, 1H), 
7.13 (s, 1H), 7.05 (s, 1H), 6.90 (s, 1H), 6.89 - 6.80 (m, 2H), 5.68 (s, 1H), 3.91 (s, 3H), 
3.85 (d, J = 5.1 Hz, 4H), 3.73 (d, J = 5.1 Hz, 4H), 2.34 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 199.17, 156.49, 148.11, 147.97, 147.78, 146.78, 145.49, 135.67, 130.12, 
128.65, 127.11, 125.14, 123.75, 123.29, 120.70, 116.08, 110.42, 107.50, 66.82, 55.97, 
45.48, 12.83; HR-MS (ESI) m/z: calcd for C24H25N2O4 [M+H]
+ 405.1809, found 
405.1810. Purity: 96.5% (by HPLC). 
(E)-3-(3-hydroxy-4-methoxyphenyl)-2-methyl-1-(2-(methylamino)quinolin-4-yl
)prop-2-en-1-one (29g). Yellow solid (56 mg, 40.2% over two steps). 1H NMR (300 
MHz, CDCl3) δ 7.75 (dt, J = 8.2, 1.3 Hz, 1H), 7.53 (dd, J = 8.9, 7.6 Hz, 2H), 7.21 - 
7.13 (m, 2H), 7.04 (d, J = 2.0 Hz, 1H), 6.92 - 6.81 (m, 2H), 6.59 (s, 1H), 5.35 (s, 1H), 
3.89 (s, 3H), 3.06 (s, 3H), 2.31 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 198.80, 156.52, 
148.06, 147.65, 146.83, 145.66, 135.48, 130.24, 128.57, 125.88, 125.35, 123.67, 
122.72, 120.65, 116.29, 110.54, 109.13, 55.95, 28.79, 12.78; HR-MS (ESI) m/z: calcd 
for C21H21N2O3 [M+H]
+ 349.1547, found 327.1555. Purity: 96.0% (by HPLC). 
(E)-1-(2-(ethylamino)quinolin-4-yl)-3-(3-hydroxy-4-methoxyphenyl)-2-methylp
rop-2-en-1-one (29h). Yellow solid (63 mg, 43.5% over two steps). 1H NMR (300 
MHz, CDCl3) δ 7.72 (d, J = 8.5 Hz, 1H), 7.64 - 7.49 (m, 2H), 7.18 - 7.14 (m, 2H), 
7.04 (d, J = 1.8 Hz, 1H), 6.90 (dd, J = 8.5, 1.7 Hz, 1H), 6.84 (d, J = 8.4 Hz, 1H), 6.58 
(s, 1H), 4.90 (s, 1H), 3.89 (s, 3H), 3.60 - 3.48 (m, 2H), 2.31 (s, 3H), 1.27 (m, 3H); 13C 
NMR (75 MHz, CDCl3) δ 198.94, 155.95, 148.10, 147.90, 146.74, 145.68, 135.52, 
130.12, 128.61, 126.19, 125.32, 123.63, 122.62, 120.77, 116.34, 110.57, 109.21, 
55.95, 36.67, 29.70, 14.95; HR-MS (ESI) m/z: calcd for C22H23N2O3 [M+H]
+ 
363.1703, found 363.1702. Purity: 96.8% (by HPLC). 
(E)-1-(2-(cyclopropylamino)quinolin-4-yl)-3-(3-hydroxy-4-methoxyphenyl)-2-
methylprop-2-en-1-one (29i). Yellow solid (55 mg, 36.7% over two steps). 1H NMR 
(300 MHz, CDCl3) δ 7.62 (d, J = 8.5 Hz, 1H), 7.49 - 7.43 (m, 2H), 7.19 - 7.12 (m, 
1H), 7.10 (s, 1H), 6.95 (s, 2H), 6.90 - 6.83 (m, 1H), 6.79 (d, J = 8.5 Hz, 1H), 5.47 (s, 
1H), 3.84 (s, 3H), 2.62 - 2.49 (m, 1H), 2.28 (s, 3H), 1.18 (s, 4H); 13C NMR (75 MHz, 
CDCl3) δ 198.98, 176.06, 157.43, 147.79, 146.86, 145.75, 135.56, 130.27, 128.62, 
125.99, 125.40, 123.51, 122.95, 121.10, 116.45, 115.52, 110.60, 107.84, 55.96, 29.70, 
24.01, 12.82; HR-MS (ESI) m/z: calcd for C23H23N2O3 [M+H]
+ 375.1703, found 
327.1709. Purity: 96.4% (by HPLC). 
(E)-3-(3-hydroxy-4-methoxyphenyl)-1-(2-((4-methoxybenzyl)amino)quinolin-4-
yl)-2-methylprop-2-en-1-one (29j). Yellow solid (103 mg, 56.7% over two steps). 1H 
NMR (300 MHz, CDCl3) δ 7.68 (d, J = 8.4 Hz, 1H), 7.51 - 7.40 (m, 2H), 7.23 - 7.18 
(s, 2H), 7.10 (dd, J = 11.3, 3.8 Hz, 1H), 7.05 (s, 1H), 6.93 (s, 1H), 6.77 - 6.74 (m, 4H), 
6.49 (s, 1H), 5.14 (s, 1H), 4.54 (s, 2H), 3.79 (s, 3H), 3.68 (s, 3H), 2.20 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 198.83, 158.93, 155.68, 148.14, 147.94, 147.77, 146.70, 
145.57, 135.53, 130.93, 130.12, 129.09, 128.61, 126.47, 125.32, 123.71, 122.81, 
120.96, 116.24, 114.09, 110.50, 109.59, 55.94, 55.29, 45.40, 29.71; HR-MS (ESI) m/z: 
calcd for C28H27N2O4 [M+H]
+ 455.1965, found 455.1969. Purity: 95.8% (by HPLC). 
(E)-3-(3-hydroxy-4-methoxyphenyl)-1-(2-methoxyquinolin-4-yl)-2-methylprop-
2-en-1-one (29k). Yellow solid (88 mg, 63.0% over two steps). 1H NMR (300 MHz, 
CDCl3) δ 7.90 (d, J = 8.4 Hz, 1H), 7.68 - 7.62 (m, 2H), 7.42 - 7.31 (m, 1H), 7.14 (s, 
1H), 7.05 (d, J = 1.8 Hz, 1H), 6.91 - 6.77 (m, 3H), 5.62 (s, 1H), 4.11 (s, 3H), 3.91 (s, 
3H), 2.34 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 198.27, 161.47, 148.94, 147.76, 
146.93, 146.85, 145.45, 135.63, 130.00, 128.58, 127.63, 125.35, 124.67, 123.76, 
122.59, 116.09, 111.41, 110.38, 55.95, 53.64, 12.83; HR-MS (ESI) m/z: calcd for 
C21H20NO4 [M+H]
+ 350.1387, found 350.1392. Purity: 96.0% (by HPLC). 
(E)-3-(3-hydroxy-4-methoxyphenyl)-2-methyl-1-(quinolin-4-yl)prop-2-en-1-one 
(29l). White solid (92 mg, 72.0% over two steps). 1H NMR (300 MHz, CDCl3) δ 8.88 
(d, J = 4.3 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.66 (dd, J = 
11.2, 4.1 Hz, 1H), 7.47 (dd, J = 11.2, 4.0 Hz, 1H), 7.28 (d, J = 4.3 Hz, 1H), 7.00 - 6.90 
(m, 2H), 6.82 - 6.74 (m, 2H), 3.80 (s, 3H), 2.28 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
198.44, 149.27, 148.30, 148.14, 147.22, 146.51, 145.86, 135.69, 130.09, 129.57, 
128.40, 127.57, 125.53, 123.62, 119.20, 116.43, 110.61, 55.94, 29.70; HR-MS (ESI) 
m/z: calcd for C20H18NO3 [M+H]
+ 320.1281, found 320.1286. Purity: 98.2% (by 
HPLC). 
(E)-4-(3-(3-hydroxy-4-methoxyphenyl)-2-methylacryloyl)quinolin-2(1H)-one 
(29m). Yellow solid (72 mg, 53.7% over two steps). 1H NMR (300 MHz, CDCl3) δ 
12.71 (s, 1H), 7.44 (s, 2H), 7.39 (d, J = 8.2 Hz, 1H), 7.23 (s, 1H), 7.12 (s, 1H), 7.02 (s, 
1H), 6.84 (d, J = 7.8 Hz, 1H), 6.76 (d, J = 8.1 Hz, 1H), 6.62 (s, 1H), 6.13 (s, 1H), 3.81 
(s, 3H), 2.24 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 197.04, 163.73, 151.34, 148.13, 
147.27, 145.59, 138.70, 134.95, 131.36, 128.37, 126.12, 124.05, 123.28, 119.17, 
118.02, 116.77, 116.31, 110.52, 55.97, 29.70; HR-MS (ESI) m/z: calcd for 
C20H18NO4[M+H]
+ 336.1230, found 336.1233. Purity: 92.5% (by HPLC). 
Ethyl(E)-4-(3-(3-hydroxy-4-methoxyphenyl)-2-methylacryloyl)quinoline-2-car
boxylate(29n). Yellow solid (82 mg, 52.4% over two steps). 1H NMR (300 MHz, 
CDCl3) δ 8.26 (d, J = 8.5 Hz, 1H), 8.04 (s, 1H), 7.73 - 7.64 (m, 2H), 7.54 (t, J = 8.1 
Hz, 1H), 7.03 - 6.87 (m, 2H), 6.82 - 6.66 (m, 2H), 4.44 (q, J = 7.1 Hz, 2H), 3.75 (s, 
3H), 2.27 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 197.89, 
164.90, 148.16, 147.78, 147.61, 147.56, 147.38, 145.62, 135.55, 130.98, 130.67, 
129.42, 128.28, 126.50, 125.28, 123.89, 119.03, 116.28, 110.50, 62.46, 55.90, 29.67, 
14.30; HR-MS (ESI) m/z: calcd for C23H22NO5 [M+H]
+ 392.1492, found 392.1493. 
Purity: 95.1% (by HPLC). 
1.11 2-Chloroquinoline-4-carbaldehyde (34). Intermediate 33 was synthesized 
according to literature report [40]. 34 was then prepared as the same procedures of 19 
with 33 (5.0 g, 25.8 mmol) and Dess-Martin oxidant (12.1 g, 28.4 mmol) as the 
reagents. White solid, 84.0%. 1H NMR (300 MHz, CDCl3) δ 10.46 (s, 1H), 8.94 (dd, J 
= 8.5, 1.5 Hz, 1H), 8.15 - 8.07 (m, 1H), 7.87 - 7.70 (m, 3H)；13C NMR (75 MHz, 
CDCl3) δ 191.10, 150.68, 149.20, 139.51, 131.30, 129.45, 129.10, 127.28, 124.49, 
122.79; ESI-MS m/z [M+Na]+ 214.0. 
1.12 1-(2-Chloroquinolin-4-yl)propan-1-ol (35). 35 was prepared as the same 
procedures of 20. Colorless oil, yield 72.9%. 1H NMR (300 MHz, CDCl3) δ 8.00 - 
7.93 (m, 1H), 7.93 - 7.86 (m, 1H), 7.71 - 7.62 (m, 1H), 7.53 (s, 1H), 7.52 - 7.44 (m, 
1H), 5.35 (dd, J = 7.7, 4.2 Hz, 1H), 3.05 (s, 1H), 1.99 - 1.76 (m, 2H), 1.04 (t, J = 7.4 
Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 153.88, 151.00, 147.89, 130.10, 129.13, 
126.72, 124.24, 123.10, 118.83, 70.97, 31.19, 10.11; ESI-MS m/z [M+Na]+ 244.1. 
1.13 1-(2-Chloroquinolin-4-yl)propan-1-one (36). 36 was prepared as the same 
procedures of 21. Yellow solid, yield 65.0%. 1H NMR (300 MHz, CDCl3) δ 8.19 (d, J 
= 8.2 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.81 - 7.72 (m, 1H), 7.64 - 7.56 (m, 1H), 7.51 
(s, 1H), 3.02 (q, J = 7.2 Hz, 2H), 1.28 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) 
δ 203.03, 150.07, 148.79, 146.79, 130.99, 129.05, 128.25, 125.36, 122.71, 120.24, 
35.93, 7.88; ESI-MS m/z [M+Na]+ 242.0. 
1.14 General procedures for the preparation of 37a-c. To a solution of 36 (150 mg, 
0.68 mml) in 2 mL EtOH in sealed tube was added secondary amines (3.4 mmol). The 
mixture was stirred at 80 °C for 6 h. Then, the mixture was concentrated in vacuo to 
afford the crude products, which was purified by column chromatography with 
petroleum/ethyl acetate (2:1) to give 37a-c as yellow solids. 
1-(2-(Dimethylamino)quinolin-4-yl)propan-1-one (37a). Yellow solid (135 mg, 
86.5%). 1HNMR (300 MHz, CDCl3) δ 7.88 (d, J = 8.3 Hz, 1H), 7.74 (d, J = 8.5 Hz, 
1H), 7.58 - 7.50 (m, 1H), 7.26 - 7.18 (m, 1H), 6.95 (s, 1H), 3.23 (s, 6H), 2.99 (q, J = 
7.2 Hz, 2H), 1.27 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 205.53, 156.66, 148.97, 
146.30, 129.84, 126.93, 124.76, 122.63, 118.06, 106.85, 38.02, 36.08, 29.69; ESI-MS 
m/z [M+Na]+ 251.1.  
1-(2-(Pyrrolidin-1-yl)quinolin-4-yl)propan-1-one (37b). Yellow solid (142 mg, 
81.8%). 1H NMR (300 MHz, CDCl3) δ 7.91 - 7.84 (m, 1H), 7.74 (d, J = 8.4 Hz, 1H), 
7.58 - 7.50 (m, 1H), 7.20 (d, J = 7.7 Hz, 1H), 6.78 (s, 1H), 3.62 (s, 4H), 2.99 (q, J = 
7.2 Hz, 2H), 2.05 (s, 4H), 1.27 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 205.52, 154.79, 
149.36, 146.05, 129.81, 126.73, 124.88, 122.26, 118.20, 108.08, 46.89, 36.09, 25.51, 
8.10; ESI-MS m/z [M+Na]+ 277.1. 
1-(2-Morpholinoquinolin-4-yl)propan-1-one (37c). Yellow solid (164 mg, 
88.8%). 1H NMR (300 MHz, CDCl3) δ 7.95 - 7.84 (m, 1H), 7.75 (d, J = 8.4 Hz, 1H), 
7.64 - 7.53 (m, 1H), 7.33 - 7.24 (m, 1H), 7.03 (s, 1H), 3.86 (t, J = 4.8 Hz, 4H), 3.72 (t, 
J = 4.8 Hz, 4H), 2.99 (q, J = 7.2 Hz, 2H), 1.28 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 205.28, 156.59, 148.55, 146.72, 130.06, 127.31, 124.79, 123.70, 118.96, 
107.15, 66.77, 45.59, 36.11, 8.06; ESI-MS m/z [M+Na]+ 293.1. 
1.15 General procedures for the preparation of 39a-d. To a solution of 35 (100 mg, 
0.45 mmol) in 2 mL EtOH in sealed tube was added primary amines (4.5 mmol). The 
mixture was stirred at 150 °C for 2 d. Then, the mixture was concentrated in vacuo to 
afford the crude products 38a-d. 38a-d were dissolved in 5 mL DMSO, IBX (150 mg, 
0.56 mmol) was added. The reactions were stirred for 30 min, then the mixtures were 
diluted with 50 mL EtOAc, then washed with water (20 mL × 3), saturated brine, 
dried over anhydrous Na2SO4, and concentrated in vacuo to afford crude products, 
which was purified by column chromatography with petroleum/ethyl acetate (2:1) to 
give 39a-d. 
1-(2-(Methylamino)quinolin-4-yl)propan-1-one (39a). Colorless oil (55 mg, 
56.9%). 1H NMR (300 MHz, CDCl3) δ 7.96 - 7.86 (m, 1H), 7.74 (d, J = 8.4 Hz, 1H), 
7.56 (m, 1H), 7.30 - 7.19 (m, 1H), 6.71 (s, 1H), 5.00 (s, 1H), 3.09 (d, J = 4.4 Hz, 3H), 
2.94 (q, J = 7.3 Hz, 2H), 1.25 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
205.02, 156.61, 148.84, 146.08, 130.00, 126.64, 125.00, 123.00, 119.01, 109.49, 
35.92, 28.65, 8.03; ESI-MS m/z [M+Na]+ 237.1. 
1-(2-(Ethylamino)quinolin-4-yl)propan-1-one (39b). Colorless oil (51 mg, 
49.1%). 1H NMR (300 MHz, CDCl3) δ 7.90 (d, J = 8.2 Hz, 1H), 7.71 (d, J = 8.4 Hz, 
1H), 7.55 (t, J = 7.7 Hz, 1H), 7.25 (d, J = 8.5 Hz, 1H), 6.71 (s, 1H), 4.80 (s, 1H), 3.56 
(d, J = 6.6 Hz, 2H), 2.95 (d, J = 7.3 Hz, 2H), 1.36 - 1.19 (m, 6H); 13C NMR (75 MHz, 
CDCl3) δ 205.05, 155.97, 148.99, 146.05, 129.94, 126.73, 124.97, 122.94, 119.05, 
109.52, 36.55, 35.91, 14.93, 8.05; ESI-MS m/z [M+Na]+ 253.1. 
1-(2-((4-Methoxybenzyl)amino)quinolin-4-yl)propan-1-one (39d). Colorless oil 
(65 mg, 45.0%). 1H NMR (300 MHz, CDCl3) δ 7.95 - 7.88 (m, 1H), 7.74 (d, J = 8.4 
Hz, 1H), 7.60 - 7.50 (m, 1H), 7.30 (d, J = 8.2 Hz, 2H), 7.26 - 7.20 (m, 1H), 6.89 - 
6.82 (m, 2H), 6.68 (s, 1H), 5.12 (d, J = 5.6 Hz, 1H), 4.64 (d, J = 5.4 Hz, 2H), 3.77 (s, 
3H), 2.87 (d, J = 7.2 Hz, 2H), 1.24 - 1.13 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 
204.95, 158.98, 155.69, 148.89, 145.89, 131.08, 130.00, 129.19, 126.86, 125.04, 
123.16, 119.24, 114.07, 109.99, 55.30, 45.29, 35.83, 8.06; ESI-MS m/z [M+Na]+ 
343.2. 
1.16 4-Propionylquinoline-2-carbonitrile (40). To a solution of 36 (500 mg, 2.25 
mmol) in 10 mL DMF was added Ph3(PPh3)4 (260 mg, 0.25mmol), Zn(CN)2 (320 mg, 
2.7 mmol), the mixture was stirred at 120 °C for 2 h under nitrogen atmosphere. Then, 
the mixture was diluted with 50 mL EtOAc, washed with water (20 mL × 3), saturated 
brine, dried over anhydrous Na2SO4, and concentrated in vacuo to afford crude 
products, which was purified by column chromatography with petroleum/ethyl acetate 
(30:1) to give 40 as a yellow solid (415 mg, 87.0%). 1H NMR (300 MHz, CDCl3) δ 
8.21 (d, J = 8.5 Hz, 1H), 8.07 (d, J = 7.8 Hz, 1H), 7.82 - 7.75 (m, 1H), 7.66 - 7.59 (m, 
1H), 7.53 (s, 1H), 3.04 (q, J = 7.6, 5.3 Hz, 2H), 1.28 (d, J = 6.3 Hz, 3H); 13C NMR 
(75 MHz, CDCl3) δ 13C NMR (75 MHz, CDCl3) δ 202.10, 182.78, 145.76, 132.51, 
130.02, 128.06, 127.28, 124.36, 121.70, 120.13, 119.24, 34.95, 6.89; ESI-MS m/z 
[M+Na]+ 211.1. 
1.17 1-(2-Methoxyquinolin-4-yl)propan-1-one (41). To a solution of 36 (150 mg, 
0.68 mml) in 10 mL CH3OH was added CH3ONa (180 mg, 3.4 mmol), the mixture 
was stirred at refluxing temperature under nitrogen atmosphere for 4 h. Then, the 
mixture was extracted with EtOAc (3 × 20 mL), and the combined organic layers 
were then washed with brine, dried over anhydrous Na2SO4, and concentrated in 
vacuo to afford the crude product, which was purified by column chromatography 
with petroleum/ethyl acetate (20:1) to give 41 as yellow solid (130 mg, 88.4%). 1H 
NMR (300 MHz, CDCl3) δ 8.17 - 8.08 (m, 1H), 7.93 - 7.85 (m, 1H), 7.70 - 7.61 (m, 
1H), 7.47 - 7.38 (m, 1H), 7.06 (s, 1H), 4.10 (s, 3H), 3.00 (q, J = 7.2 Hz, 2H), 1.27 (t, J 
= 7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 204.17, 161.61, 147.53, 146.82, 129.96, 
127.73, 125.26, 125.11, 120.94, 111.68, 53.65, 35.72, 8.01; ESI-MS m/z [M+Na]+ 
238.1. 
1.18 4-Propionylquinolin-2(1H)-one (42). To a solution of 36 (100 mg, 0.46 mmol) 
in the mixture solvent of H2O (10 mL) and AcOH (2 mL) was added CH3SO2Na (92 
mg, 0.92 mmol), the mixture was stirred at 90 °C overnight. Then, the mixture was 
neutralized by saturated NaHCO3 aqueous, and extracted with EtOAc (3 × 20 mL), 
and the combined organic layers were then washed with brine, dried over anhydrous 
Na2SO4, and concentrated in vacuo to afford the crude product, which was purified by 
column chromatography with petroleum/ethyl acetate (20:1) to give 42 as a white 
solid (80 mg, 87.3%). 1H NMR (300 MHz, DMSO-d6) δ 12.01 (s, 1H), 7.67 (d, J = 8.2 
Hz, 1H), 7.58 - 7.51 (m, 1H), 7.38 (d, J = 8.2 Hz, 1H), 7.22 - 7.14 (m, 1H), 6.89 (s, 
1H), 3.10 - 2.97 (m, 2H), 1.16 - 1.02 (m, 3H); 13C NMR (75 MHz, DMSO-d6) δ 
204.19, 161.18, 148.22, 139.41, 130.77, 125.67, 122.11, 120.64, 115.75, 115.16, 
35.14, 7.49; ESI-MS m/z [M+Na]+ 224.1. 
1.19 1-(Quinolin-4-yl)propan-1-one (45). 45 was prepared as the same procedures of 
21 with the commercially available 43 (500 mg, 3.18 mmol) as the starting material. 
Colorless oil (320 mg, 54.3% over two steps). 1H NMR (300 MHz, CDCl3) δ 8.89 (d, 
J = 4.4 Hz, 1H), 8.21 (dd, J = 8.6, 1.4 Hz, 1H), 8.12 - 8.03 (m, 1H), 7.70 - 7.63 (m, 
1H), 7.56 - 7.48 (m, 1H), 7.43 (d, J = 4.4 Hz, 1H), 2.95 (q, J = 7.2 Hz, 2H), 1.19 (t, J 
= 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 204.42, 149.65, 148.88, 143.56, 129.82, 
129.76, 128.03, 125.27, 123.73, 118.82, 35.69, 7.97; ESI-MS m/z [M+Na]+ 208.1. 
2. Biology.  
2.1 Materials. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2-H-tetrazolium bromide 
(MTT), propidium iodide (PI), the Annexin V-FITC apoptosis detection kit, 
5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine iodide (JC-1) were 
purchased from Nanjing KeyGen Biotech Co. Ltd. (Nanjing, China). Goat antimouse 
IgG/Alexa-Fluor 488 antibody was purchased from Jackson ImmunoResearch in USA. 
Primary antibodies against cdc25c, cdc2, cyclin B1, Bax, Bad, Bcl-2 and Bcl-xl were 
purchased from Beyotime (Jiangsu, China). The purified tubulin polymerization kit 
was purchased from Cytoskeleton Inc. (Denver, USA). Other reagents were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified. 
2.2 Cell Lines and Cell Culture. Human chronic myelogenous leukemia cells 
(K562), hepatocellular carcinoma cells (HepG2), epidermoid carcinoma of the 
nasopharynx cells (KB), human colon cancer cells (HCT-8), and human breast cancer 
cells (MDA-MB-231) were grown in RPMI 1640 medium (KeyGen Biotech Co. Ltd., 
Nanjing, China). Human umbilical vein endothelial cells (HUVECs) were grown in 
F12K medium (KeyGen Biotech Co. Ltd., Nanjing, China). The medium for all cell 
lines were supplemented with 10% fetal bovine serum (Life Technologies, USA), 100 
μg/mL streptomycin (Life Technologies, USA), and 100 U/mL penicillin (Life 
Technologies, USA) and maintained at 37 °C in a humidified atmosphere with 5% 
CO2. 
2.3 MTT Assay. The overall growth of human cancer cell lines was determined using 
the colorimetric MTT assay. Briefly, the cell lines were incubated at 37 °C in a 
humidified 5% CO2 incubator for 24 h in 96-well plates prior to the experiments. 
K562, HepG2, KB, HCT-8, and MDA-MB-231 were seeded at a density of 5 × 103 
cells/well. After removal of medium, 100 μL of fresh medium containing the test 
compound at different concentrations was added to each well and incubated at 37 °C 
for 24 or 72 h. The percentage of DMSO in the medium was not exceeded 0.25%. The 
number of living cells after 72 h (or 24 h) of culture in the presence (or absence: 
control) of the various compounds is directly proportional to the intensity of the blue 
color of media, which is quantitatively measured by spectrophotometry (Biorad, 
Nazareth, Belgium) at a 570 nm wavelength. The experiment was performed in 
quadruplicate and repeated three times. 
2.4 In Vitro Tubulin Polymerization Inhibitory Assay. The tubulin reaction mix in 
100 μL PEM buffer contained 2 mg/mL tubulin (Cytoskeleton), 80 mM 
piperazine-N,N′-bis(2-ethanesulfonic acid) sequisodium salt PIPES (pH 6.9), 0.5 mM 
EGTA, 2 mM MgCl2, and 15% glycerol. Then, the mixture was preincubated with 
compounds or vehicle DMSO on ice. PEG containing GTP was added to the final 
concentration of 3 mg/mL before detecting the tubulin polymerization reaction. After 
30 min, the absorbance was detected by a spectrophotometer at 340 nm at 37 °C every 
2 min for 60 min. The area under the curve was used to determine the concentration 
that inhibited tubulin polymerization by 50% (IC50), which was calculated with 
GraphPad Prism Software version 5.02. 
2.5 Competitive Inhibition Assays. The competitive binding activity of inhibitors 
was evaluated using a radiolabeled [3H]-colchicine competition scintillation 
proximity (SPA) assay. In brief, 0.08 μM [3H]-colchicine was mixed with 24d (1 μM, 
5 μM) or CA-4 (1 μM, 5 μM) and biotinylated porcine tubulin (0.5 μg) in a buffer of 
100 μL containing 80 mM PIPES (pH 6.8), 1mM EGTA, 10% glycerol, 1mM MgCl2, 
and 1mM GTP for 2 h at 37 °C. Then streptavidin-labeled SPA beads (80 μg) were 
added to each mixture. The radioactive counts were measured directly with a 
scintillation counter. 
2.6 Immunofluorescent Staining. K562 cells were seeded into 6-well plates and then 
treated with vehicle control 0.1% DMSO, 24d (5 nM, 10 nM, 20 nM). The cells were 
fixed with 4% paraformaldehyde and then washed with PBS for three times. After 
blocking for 20 min by adding 50-100 μL goat serum albumin at room temperature, 
cells were incubated with a monoclonal antibody (anti-α-tubulin) at 37 °C for 2 h. 
Then the cells were washed three times by PBS following staining by fluorescence 
secondary antibody and labeling of nuclei by 4,6-diamidino-2-phenylindole (DAPI). 
Cells were finally visualized on a Zeiss LSM 570 laser scanning confocal microscope 
(Carl Zeiss, Germany). 
2.7 Molecular Modeling. In our study, the X-ray structure of CA-4-α,β-tubulin 
complex was downloaded from the Protein Data Bank (PDB code 5lyj). The protein 
was prepared by removal of the stathmin-like domain, subunits C and D, water 
molecules and CA-4 using Discovery Studio modules. The docking procedure was 
performed by employing DOCK program in Discovery Studio 3.0 software, and the 
structural image was obtained using PyMOL software. 
2.8 Cell Cycle Analysis. K562 cells were seeded into 6-well plates and incubated at 
37 °C in a humidified 5% CO2 incubator for 24 h, and then treated with or without 
24d at indicated concentrations for another 48 h. The collected cells were fixed by 
adding 70% ethanol at 4 °C for 12 h. Subsequently, the cells were resuspended in PBS 
containing 100 mL RNase A and 400 mL of propidium iodide for 30 min. The DNA 
content of the cells was measured using a FACS Calibur flow cytometer (Bectone 
Dickinson, San Jose, CA, USA). 
2.9 Hoechst 33342 Staining. Approximately 5 × 104 cells per well were plated in 
six-well plates, and the cells were then incubated with 0, 5, 10, and 20 nM 24d for 48 
h. After incubation, cells were washed with PBS, fixed in 4% paraformaldehyde for 
30 min, and then stained with 20 μg/mL Hoechst 33342 for 15 min at room 
temperature in the dark. Cells were then assessed by fluorescence microscopy for 
morphological changes after 24d treatment. 
2.10 Cell Apoptosis Analysis. After treatment with or without 24d at indicated 
concentrations for 48 h, the cells were washed twice in PBS, centrifuged and 
resuspended in 500 mL AnnexinV binding buffer. The cells were then harvested, 
washed and stained with 5 mL Annexin V-APC and 5 mL 7-AAD in the darkness for 
15 min. Apoptosis was analyzed using a FACS Calibur flow cytometer (Bectone 
Dickinson, San Jose, CA, USA). 
2.11 Mitochondrial Membrane Potential Analysis. After treatment with vehicle 
control 0.1% DMSO, 24d (5 nM, 10 nM, and 20 nM) for 48 h, the cells were washed 
in PBS and resuspended in 500 μL JC-1 incubation buffer at 37 °C for 15 min. The 
percentage of cells with healthy or collapsed mitochondrial membrane potentials was 
monitored by flow cytometry analysis (Bectone-Dickinson, San Jose, CA, USA). 
Measurement of Intracellular ROS Generation. Intracellular ROS production was 
detected by using the peroxide-sensitive fluorescent probe DCF-DA. In brief, after 
treatment with 0, 5, 10, and 20 nM 24d for 48 h, the cells were incubated with 10 mM 
DCF-DA at 37 °C for 15 min. The intracellular ROS mediated oxidation of DCF-DA 
to the fluorescent compound 2′,7′-dichlorofluorescein (DCF). Then cells were 
harvested, and the pellets were suspended in 1 mL PBS. Samples were analyzed at an 
excitation wavelength of 480 nm and an emission wavelength of 525 nm by flow 
cytometry on a FC500 cytometer (Beckman Coulter). 
2.12 Transwell Migration and Invasion Assay. In the invasion assay, diluted 
Matrigel was added to the upper chamber whereas for migration assay, the chamber 
was not coated with Matrigel. MDB-MB231 cells (1 × 105 cells/well) were cultured in 
the upper chambers of 24-well transwell plates (8 μm pore, Corning Costar), and 24d 
(0, 2, 5, and 10 nM) was treated on the lower surface for 48 h. The cells on the upper 
surface of the membrane were removed, and the migrated or invaded cells on the 
bottom surface of the membranes were stained with crystal violet. The images of 
migrated or invaded cells at the bottom part of the chamber were captured and the 
number of migrated or invaded cells determined by counting cells in at least three 
fields from random sites. 
2.13 Wound Healing Assays. K562 cells were grown in 6-well plates for 24 h. 
Scratches were made in confluent monolayers using 200 μL pipette tips. Then, 
wounds were washed twice with PBS to remove non-adherent cell debris. The media 
containing different concentrations (0, 5, 10, and 20 nM) of 24d were added to the 
petri dishes. Cells which migrated across the wound area were photographed using 
phase contrast microscopy at 0 h and 24 h. The migration distance of cells migrated in 
to the wound area was measured manually. 
2.14 Tube Formation Assay. EC Matrigel matrix was thawed at 4 °C overnight, and 
HUVECs suspended in F12K were seeded in 96-well culture plates at a cell density of 
50,000 cells/well after polymerization of the Matrigel at 37 °C for 30 min. They were 
then treated with 20 μL different concentrations of 24d or vehicle for 6 h at 37 °C. 
Then, the morphological changes of the cells and tubes formed were observed and 
photographed under inverted microscope (OLYMPUS, Japan). 
2.15 Solubility Evaluation. Compounds 1 and 24d were added to phosphate buffer 
(50 mM, pH 7.4) at 20 °C. After shaking and centrifuging, the supernatant was taken 
to determine the concentration of compounds 1 and 24d in each solvent for 
calculation of the corresponding solubility. The samples (10 μL each) were analyzed 
by HPLC (Shimadzu DGU-20A3R) on Shimadzu-GL WondaSil C18-WR column. 
The mobile phase was acetonitrile-water (70/30, v/v) at a flow rate of 1.0 mL/min 
with the detection wavelength at 254 nm. This experiment was repeated in triplicates. 
2.16 Acute Toxicity Determination. Five-week-old male Institute of Cancer 
Research (ICR) mice were purchased from Shanghai SLAC Laboratory Animals Co. 
Ltd. An acute toxicity study by intravenous injection was conducted according to the 
guidelines of the Organization for Economic Co-operation and Development. The 
animals were weighed and at random divided into five groups of ten animals. Then, 
the mice were intravenous injected with 24d (409.6, 512, 640, 800, and 1000 mg/kg) 
in a vehicle of 10% DMF/2% Tween 80/88% saline. The animals were observed 
continuously for 14 days. 
2.17 In Vivo Anti-tumor Effect Evaluation. A total of 1 × 106 H22 cells were 
subcutaneously inoculated into the right flank of ICR mice according to protocols of 
tumor transplant research. After incubation for one day, mice were weighted and at 
random divided into eight groups with eight animals per groups. The groups treated 
with 24d and CA-4 were administered 10, 20 mg/kg in a vehicle of 10% DMF/2% 
Tween 80/88% saline, respectively. The groups treated with 24d-HCl were 
administered 10, 20 mg/kg in a vehicle of saline. The positive control group was 
treated with PTX (8 mg/kg) every 2 days by intravenous injection. The negative 
control group received a vehicle of 10% DMF/2% Tween 80/88% saline through 
intravenous injection. Treatments of 24d, 24d-HCl and CA-4 were conducted at a 
frequency of intravenous injection one dose per day for a total 21 consecutive days 
while the positive group was treated with PTX one dose per two days. Body weights 
and tumor volumes were measured every 2 days. After the treatments, all the mice 
were sacrificed and weighed. The following formula was used to determine tumor 
volumes: tumor volume = L × W2/2, where L is the length and W is the width. Ratio 
of inhibition of tumor (%) = (1 − average tumor weight of treated group/average 
tumor weight of control group) × 100%. All procedures were performed following 
institutional approval in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals. 
2.18 Immunohistochemistry assay. Slides from mouse tissues (24d-treated group at 
20 mg/kg) were embedded in paraffin were cut to a section of 4 μm, deparaffinized, 
and treated with citrate buffer. Then, they were blocked with avidin/biotin for 20 min. 
The slides were incubated with CD31 overnight at 4 °C. Next, the slides were treated 
with secondary antibody with horseradish peroxidase goat anti-rabbit for 1-3 h and 
developed with 3, 3-diaminobenzidine. Finally, the slides were counterstained with 
hematoxylin. The mean microvessel density (MVD) was measured by calculating the 
CD31-positive cells in randomly selected areas in each section using image analysis 
software and then analyzed with OriginPro 8.0 software. 
SUPPORTING INFORMATION AVAILABLE 
1H and 13C NMR spectra for key intermediates and all target compounds, HPLC trace 
for compound 24d and Molecular Formula Strings are available free of charge via the 
internet at http://pubs.acs.org.  
The statement for Molecular modeling (PDB) file: Authors will release the atomic 
coordinates and experimental data upon article publication.  
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CA-4, Combretastatin A-4; MEM, 2-Methoxyethoxymethyl chloride; m-CPBA, 
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